<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2605210756
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Golimara
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FINGOLIMOD HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4436.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA27
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Golimara is</strong></p><p>The active substance of Golimara is fingolimod.</p><p>&nbsp;</p><p><strong>What Golimara is used for</strong></p><p>Golimara is used in adults and in children and adolescents (10 years of age and above) to treat relapsing-remitting multiple sclerosis (MS), more specifically in:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients who have failed to respond despite treatment with an MS treatment.</p><p>or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients who have rapidly evolving severe MS.</p><p>&nbsp;</p><p>Golimara does not cure MS, but it helps to reduce the number of relapses and to slow down the</p><p>progression of physical disabilities due to MS.</p><p>&nbsp;</p><p><strong>What multiple sclerosis is</strong></p><p>MS is a long-term condition that affects the central nervous system (CNS), comprised of the brain and</p><p>spinal cord. In MS inflammation destroys the protective sheath (called myelin) around the nerves in</p><p>the CNS and stops the nerves from working properly. This is called demyelination.</p><p>&nbsp;</p><p>Relapsing-remitting MS is characterised by repeated attacks (relapses) of nervous system symptoms</p><p>that reflect inflammation within the CNS. Symptoms vary from patient to patient but typically involve</p><p>walking difficulties, numbness, vision problems or disturbed balance. Symptoms of a relapse may</p><p>disappear completely when the relapse is over, but some problems may remain.</p><p>&nbsp;</p><p><strong>How Golimara works</strong></p><p>Golimara helps to protect against attacks on the CNS by the immune system by reducing the ability of some white blood cells (lymphocytes) to move freely within the body and by stopping them from reaching the brain and spinal cord. This limits nerve damage caused by MS. Golimara also reduces some of the immune reactions of your body.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Golimara</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a <strong>lowered immune response</strong> (due to an immunodeficiency syndrome, a disease or</p><p>to medicines that suppress the immune system).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a <strong>severe active infection or active chronic infection</strong> such as hepatitis or tuberculosis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an <strong>active cancer</strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>severe liver problems</strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if, in the last 6 months, you have had heart attack, angina, stroke or warning of a stroke</strong></p><p><strong>or certain types of heart failure.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have certain types of <strong>irregular or abnormal heartbeat</strong> (arrhythmia), including patients</p><p>in whom the electrocardiogram (ECG) shows prolonged QT interval before starting Golimara.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are taking or have recently taken medicine for irregular heartbeat</strong> such as quinidine,</p><p>disopyramide, amiodarone or sotalol.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are allergic</strong> to fingolimod or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>If this applies to you, <strong>tell your doctor before taking Golimara</strong>.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before taking Golimara:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have severe breathing problems during sleep (severe sleep apnoea).</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have been told you have an abnormal electrocardiogram.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you suffer from symptoms of slow heart rate (e.g. dizziness, nausea or palpitations).</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are taking or have recently taken medicines that slow your heart rate</strong> (such as beta</p><p>blockers, verapamil, diltiazem or ivabradine, digoxin, anticholinesteratic agents or pilocarpine).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have a history of sudden loss of consciousness or fainting (syncope).</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you plan to get vaccinated.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have never had chickenpox.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have or have had visual disturbances</strong> or other signs of swelling in the central vision</p><p>area (macula) at the back of the eye (a condition known as macular oedema, see below),</p><p>inflammation or infection of the eye (uveitis) <strong>or if you have diabetes</strong> (which can cause eye problems).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have liver problems.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>high blood pressure that cannot be controlled by medicines</strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>severe lung problems</strong> or smoker&rsquo;s cough.</p><p>&nbsp;</p><p>If any of these applies to you, <strong>tell your doctor before taking Golimara</strong>.</p><p>&nbsp;</p><p><u>Slow heart rate (bradycardia) and irregular heartbeat</u></p><p>At the beginning of treatment Golimara causes the heart rate to slow down. As a result, you may feel dizzy or tired or be consciously aware of your heartbeat or your blood pressure may drop. <strong>If these effects are pronounced, tell your doctor, because you may need treatment right away.</strong> Golimara can also cause an irregular heartbeat, especially after the first dose. Irregular heartbeat usually returns to normal in less than one day. Slow heart rate usually returns to normal within one month.</p><p>&nbsp;</p><p>Your doctor will ask you to stay at the surgery or clinic for at least 6 hours, with hourly pulse and</p><p>blood pressure measurements, after taking the first dose of Golimara so that appropriate measures can be taken in the event of side effects that occur at the start of treatment. You should have an electrocardiogram performed prior to the first dose of Golimara and after the 6-hour monitoring period. Your doctor may monitor your electrocardiogram continuously during that time. If after the 6-hour period you have a very slow or decreasing heart rate, or if your electrocardiogram shows abnormalities, you may need to be monitored for a longer period (at least 2 more hours and possibly overnight) until these have resolved. The same may apply if you are resuming Golimara after a break in treatment, depending on both how long the break was and how long you had been taking Golimara before the break.</p><p>&nbsp;</p><p>If you have, or if you are at risk for, an irregular or abnormal heartbeat, if your electrocardiogram is abnormal, or if you have heart disease or heart failure, Golimara may not be appropriate for you.</p><p>&nbsp;</p><p>If you have a history of sudden loss of consciousness or decreased heart rate, Golimara may not be appropriate for you. You will be evaluated by a cardiologist (heart specialist) to advise how you should start treatment with Golimara, including overnight monitoring.</p><p>&nbsp;</p><p>If you are taking medicines that can cause your heart rate to decrease, Golimara may not be appropriate for you. You will need to be evaluated by a cardiologist, who will check whether you can be switched to alternative medicine that does not decrease your heart rate in order to allow treatment with Golimara. If such a switch is impossible, the cardiologist will advise how you should start treatment with Golimara, including overnight monitoring.</p><p>&nbsp;</p><p><u>If you have never had chickenpox</u></p><p>If you have never had chickenpox, your doctor will check your immunity against the virus that causes it (varicella zoster virus). If you are not protected against the virus, you may need a vaccination before you start treatment with Golimara. If this is the case, your doctor will delay the start of treatment with Golimara until one month after the full course of vaccination is completed.</p><p>&nbsp;</p><p><u>Infections</u></p><p>Golimara lowers the white blood cell count (particularly the lymphocyte count). White blood cells fight infection. While you are taking Golimara (and for up to 2 months after you stop taking it), you may get infections more easily. Any infection that you already have may get worse. Infections could be serious and life-threatening. If you think you have an infection, have fever, feel like you have the flu or have a headache accompanied by stiff neck, sensitivity to light, nausea, and/or confusion (these may be caused by a fungal infection and may be symptoms of meningitis), contact your doctor straight away, because it could be serious and life-threatening. If you believe your MS is getting worse (e.g. weakness or visual changes) or if you notice any new symptoms, talk to your doctor straight away, because these may be the symptoms of a rare brain disorder caused by infection and called progressive multifocal leukoencephalopathy (PML). PML is a serious condition that may lead to severe disability or death.</p><p>&nbsp;</p><p>Human papilloma virus (HPV) infection, including papilloma, dysplasia, warts and HPV-related cancer, has been reported in patients treated with fingolimod. Your doctor will consider whether you need to have a vaccination against HPV before starting treatment. If you are a woman, your doctor will also recommend HPV screening.</p><p><u>&nbsp;</u></p><p><u>Macular oedema</u></p><p>Before you start Golimara, if you have or have had visual disturbances or other signs of swelling in the central vision area (macula) at the back of the eye, inflammation or infection of the eye (uveitis) or diabetes, your doctor may want you to undergo an eye examination.</p><p>&nbsp;</p><p>Your doctor may want you to undergo an eye examination 3 to 4 months after starting Golimara treatment.</p><p>&nbsp;</p><p>The macula is a small area of the retina at the back of the eye which enables you to see shapes, colours and details clearly and sharply. Golimara may cause swelling in the macula, a condition that is known as macular oedema. The swelling usually happens in the first 4 months of Golimara treatment.</p><p>&nbsp;</p><p>Your chance of developing macular oedema is higher if you have <strong>diabetes</strong> or have had an</p><p>inflammation of the eye called uveitis. In these cases your doctor will want you to undergo regular eye</p><p>examinations in order to detect macular oedema.</p><p>&nbsp;</p><p>If you have had macular oedema, talk to your doctor before you resume treatment with Golimara.</p><p>&nbsp;</p><p>Macular oedema can cause some of the same vision symptoms as an MS attack (optic neuritis). Early on, there may not be any symptoms. Be sure to tell your doctor about any changes in your vision. Your doctor may want you to undergo an eye examination, especially if:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the centre of your vision gets blurry or has shadows.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you develop a blind spot in the centre of your vision.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have problems seeing colours or fine detail.</p><p>&nbsp;</p><p><u>Liver function tests</u></p><p>If you have severe liver problems, you should not take Golimara. Golimara may affect your liver function. You will probably not notice any symptoms, but if you notice yellowing of your skin or the whites of your eyes, abnormally dark urine or unexplained nausea and vomiting, <strong>tell your doctor straight away</strong>.</p><p>&nbsp;</p><p>If you get any of these symptoms after starting Golimara, <strong>tell your doctor straight away</strong>.</p><p>&nbsp;</p><p>During the first twelve months of treatment your doctor will request blood tests to monitor your liver function. If your test results indicate a problem with your liver you may have to interrupt treatment with Golimara.</p><p>&nbsp;</p><p><u>High blood pressure</u></p><p>As Golimara causes a slight elevation of blood pressure, your doctor may want to check your blood pressure regularly.</p><p>&nbsp;</p><p><u>Lung problems</u></p><p>Golimara has a slight effect on the lung function. Patients with severe lung problems or with smoker&rsquo;s cough may have a higher chance of developing side effects.</p><p>&nbsp;</p><p><u>Blood count</u></p><p>The desired effect of Golimara treatment is to reduce the amount of white blood cells in your blood. This will usually go back to normal within 2 months of stopping treatment. If you need to have any blood tests, tell the doctor that you are taking Golimara. Otherwise, it may not be possible for the doctor to understand the results of the test and for certain types of blood test your doctor may need to take more blood than usual.</p><p>&nbsp;</p><p>Before you start Golimara, your doctor will confirm whether you have enough white blood cells in your blood and may want to repeat a check regularly. In case you do not have enough white blood cells, you may have to interrupt treatment with Golimara.</p><p>&nbsp;</p><p><u>Posterior reversible encephalopathy syndrome (PRES)</u></p><p>A condition called posterior reversible encephalopathy syndrome (PRES) has been rarely reported in</p><p>MS patients treated with fingolimod. Symptoms may include sudden onset of severe headache,</p><p>confusion, seizures and vision changes. Tell your doctor straight away if you experience any of these</p><p>symptoms during your treatment with Golimara, because it could be serious.</p><p>&nbsp;</p><p><u>Skin cancer</u></p><p>Skin cancers have been reported in MS patients treated with Golimara. Talk to your doctor straight away if you notice any skin nodules (e.g. shiny pearly nodules), patches or open sores that do not heal within weeks. Symptoms of skin cancer may include abnormal growth or changes of skin tissue (e.g. unusual moles) with a change in colour, shape or size over time. Before you start Golimara, a skin examination is required to check whether you have any skin nodules. Your doctor will also carry out regular skin examinations during your treatment with Golimara. If you develop problems with your skin, your doctor may refer you to a dermatologist, who after consultation may decide that it is important for you to be seen on a regular basis.</p><p>&nbsp;</p><p><u>Exposure to the sun and protection against the sun</u></p><p>Fingolimod weakens your immune system.</p><p>This increases your risk of developing cancers, in particular skin cancers. You should limit your</p><p>exposure to the sun and UV rays by:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wearing appropriate protective clothing.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; regularly applying sunscreen with a high degree of UV protection.</p><p>&nbsp;</p><p><strong>Elderly</strong></p><p>Experience with Golimara in elderly patients (over 65 years) is limited. Talk to your doctor if you have any concerns.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children below 10 years old as it has not been studied in MS patients in this age group.</p><p>&nbsp;</p><p>The warnings and precautions listed above also apply to children and adolescents. The following information is particularly important for children and adolescents and their caregivers:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before you start Golimara, your doctor will check your vaccination status. If you have not had certain vaccinations, it may be necessary for you to be given them before Golimara can be started.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The first time you take Golimara your doctor will monitor your heart rate and heartbeat (see &ldquo;Slow heart rate (bradycardia) and irregular heartbeat&rdquo; above).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience convulsions or fits before or whilst taking Golimara, let your doctor know.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from depression or anxiety or if you become depressed or anxious while you are taking Golimara, let your doctor know. You may need to be monitored more closely.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Golimara</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Tell your doctor if you are taking any of the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Medicines that suppress or modulate the immune system</strong>, including<strong> other medicines used</strong></p><p><strong>to treat MS</strong>, such as beta interferon, glatiramer acetate, natalizumab, mitoxantrone,</p><p>teriflunomide, dimethyl fumarate or alemtuzumab. You must not use Golimara together with such medicines as this could intensify the effect on the immune system (see also &ldquo;Do not take Golimara&rdquo;).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Corticosteroids</strong>, due to a possible added effect on the immune system.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vaccines</strong>. If you need to receive a vaccine, seek your doctor&rsquo;s advice first. During and for up to</p><p>2 months after treatment with Golimara, you should not receive certain types of vaccine (live attenuated vaccines), as they could trigger the infection that they were supposed to prevent. Other vaccines may not work as well as usual if given during this period.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Medicines that slow the heartbeat</strong> (for example beta blockers, such as atenolol). Use of Golimara together with such medicines could intensify the effect on heartbeat in the first days after starting Golimara.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Medicines for irregular heartbeat</strong>, such as quinidine, disopyramide, amiodarone or sotalol.</p><p>You must not use Golimara, if you are taking such a medicine because it could intensify the effect on irregular heartbeat (see also &ldquo;Do not take Golimara&rdquo;).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other medicines</strong>:</p><p>o&nbsp; protease inhibitors, anti-infectives such as ketoconazole, azole antifungals, clarithromycin or telithromycin.</p><p>o&nbsp; carbamazepine, rifampicine, phenobarbital, phenytoin, efavirenz or St. John&rsquo;s Wort (potential risk of reduced efficacy of Golimara).</p><p>&nbsp;</p><p><strong>Pregnancy and</strong><strong> breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p>Before you start treatment with Golimara, your doctor may ask you to do a pregnancy test in order to ensure that you are not pregnant. You should avoid becoming pregnant while taking Golimara or in the two months after you stop taking it, because there is a risk of harm to the baby. Talk with your doctor about reliable methods of birth control that you should use during treatment and for 2 months after you stop treatment.</p><p>&nbsp;</p><p><strong>If you do become pregnant while taking Golimara, stop taking the medicine and tell your doctor straight away.</strong> You and your doctor will decide what is best for you and your baby.</p><p>&nbsp;</p><p><strong>You should not breast-feed while you are taking Golimara. </strong>Golimara can pass into breast milk and there is a risk of serious side effects for the baby.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Your doctor will tell you whether your illness allows you to drive vehicles, including a bicycle, and use machines safely. Golimara is not expected to have an influence on your ability to drive and use machines.</p><p>&nbsp;</p><p>However, at initiation of treatment you will have to stay at the doctor&rsquo;s surgery or clinic for 6 hours</p><p>after taking the first dose of Golimara. Your ability to drive and use machines may be impaired during and potentially after this time period.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Treatment with Golimara will be overseen by a doctor who is experienced in the treatment of multiple sclerosis.</p><p>&nbsp;</p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not</p><p>sure.</p><p>&nbsp;</p><p><strong>Use in adults</strong></p><p><strong>The recommended dose is one hard capsule per day. </strong></p><p><strong>&nbsp;</strong></p><p><strong>Use in children and adolescents (10 years of age and above)</strong></p><p><strong>The dose depends on body weight:</strong></p><p>The recommended dose is one hard capsule per day for children and adolescents with body weight above 40 kg.</p><p>&nbsp;</p><p>Do not exceed the recommended dose.</p><p>&nbsp;</p><p>Golimara is for oral use.</p><p>&nbsp;</p><p>Take Golimara once a day with a glass of water. Golimara hard capsules should always be swallowed intact, without opening them. Golimara can be taken with or without food.</p><p>Taking Golimara at the same time each day will help you remember when to take your medicine.</p><p>&nbsp;</p><p>Your doctor may switch you directly from beta interferon, glatiramer acetate or dimethyl fumarate to</p><p>Golimara, if there are no signs of abnormalities caused by your previous treatment. Your doctor may have to do a blood test in order to exclude such abnormalities. After stopping natalizumab you may have to wait for 2-3 months before starting treatment with Golimara. To switch from teriflunomide, your doctor may advise you to wait for a certain time or to go through an accelerated elimination procedure. If you have been treated with alemtuzumab, a thorough evaluation and discussion with your doctor is required to decide if Golimara is appropriate for you.</p><p>&nbsp;</p><p>If you have questions about how long to take Golimara, talk to your doctor or your pharmacist.</p><p>&nbsp;</p><p><strong>If you take more Golimara &nbsp;than you should</strong></p><p>If you have taken too much Golimara, call your doctor straight away.</p><p>&nbsp;</p><p><strong>If you forget to take Golimara </strong></p><p>If you have been taking Golimara for less than 1 month and you forget to take 1 dose for a whole day, call your doctor before you take the next dose. Your doctor may decide to keep you under observation at the time you take the next dose.</p><p>&nbsp;</p><p>If you have been taking Golimara for at least 1 month and have forgotten to take your treatment for more than 2 weeks, call your doctor before you take the next dose. Your doctor may decide to keep you under observation at the time you take the next dose. However, if you have forgotten to take your treatment for up to 2 weeks, you can take the next dose as planned.</p><p>&nbsp;</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking Golimara </strong></p><p>Do not stop taking Golimara or change your dose without talking to your doctor first.</p><p>&nbsp;</p><p>Golimara will stay in your body for up to 2 months after you stop taking it. Your white blood cell count (lymphocyte count) may also remain low during this time and the side effects described in this leaflet may still occur. After stopping Golimara you may have to wait for 6-8 weeks before starting a new MS treatment.</p><p>&nbsp;</p><p>If you have to restart Golimara more than 2 weeks after you stop taking it, the effect on heart rate normally seen when treatment is first started may re-occur and you will need to be monitored at the doctor&rsquo;s surgery or clinic for re-initiation of treatment. Do not restart Golimara after stopping it for more than two weeks without seeking advice from your doctor.</p><p>&nbsp;</p><p>Your doctor will decide whether and how you need to be monitored after stopping Golimara.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Some side effects could be or could become serious</strong></p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coughing with phlegm, chest discomfort, fever (signs of lung disorders)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Herpes virus infection (shingles or herpes zoster) with symptoms such as blisters, burning,</p><p>itching or pain of the skin, typically on the upper body or the face. Other symptoms may be</p><p>fever and weakness in the early stages of infection, followed by numbness, itching or red</p><p>patches with severe pain.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow heartbeat (bradycardia), irregular heart rhythm</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A type of skin cancer called basal cell carcinoma (BCC) which often appears as a pearly</p><p>nodule, although it can also take other forms</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression and anxiety are known to occur with increased frequency in the MS population and have also been reported in children and adolescents treated with fingolimod.</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia with symptoms such as fever, cough, difficulty breathing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Macular oedema (swelling in the central vision area of the retina at the back of the eye) with</p><p>symptoms such as shadows or blind spot in the centre of the vision, blurred vision, problems</p><p>seeing colours or details</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in blood platelets which increases risk of bleeding or bruising</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Malignant melanoma (a type of skin cancer which usually develops from an unusual mole).</p><p>Possible signs of melanoma include moles which may change size, shape, elevation or colour</p><p>over time or new moles. The moles may itch, bleed or ulcerate.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsion, fits (more frequent in children and adolescents than in adults)</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect up to 1 in 1,000 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A condition called posterior reversible encephalopathy syndrome (PRES). Symptoms may</p><p>include sudden onset of severe headache, confusion, seizures and/or vision disturbances.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lymphoma (a type of cancer that affects the lymph system)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Squamous cell carcinoma: a type of skin cancer which may present as a firm red nodule, a sore</p><p>with crust or a new sore on an existing scar</p><p>&nbsp;</p><p><strong>Very rare</strong> (may affect up to 1 in 10,000 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Electrocardiogram anomaly (T-wave inversion)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tumour related to infection with human herpes virus 8 (Kaposi&rsquo;s sarcoma)</p><p>&nbsp;</p><p><strong>Not known</strong> (frequency cannot be estimated from the available data):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions, including symptoms of rash or itchy hives, swelling of lips, tongue or face,</p><p>which are more likely to occur on the day you start Golimara treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risk of a rare brain infection called progressive multifocal leukoencephalopathy (PML). The</p><p>symptoms of PML may be similar to an MS relapse. Symptoms might also arise that you might</p><p>not become aware of by yourself, such as changes in mood or behaviour, memory lapses, speech and communication difficulties, which your doctor may need to investigate further to rule out PML. Therefore, if you believe your MS is getting worse or if you or those close to you notice any new or unusual symptoms, it is very important that you speak to your doctor as soon as possible.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cryptococcal infections (a type of fungal infection), including cryptococcal meningitis with</p><p>symptoms such as headache accompanied by stiff neck, sensitivity to light, nausea and/or</p><p>confusion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Merkel cell carcinoma (a type of skin cancer). Possible signs of Merkel cell carcinoma include</p><p>flesh-coloured or bluish-red, painless nodule, often on the face, head or neck. Merkel cell</p><p>carcinoma can also present as a firm painless nodule or mass. Long-term exposure to the sun</p><p>and a weak immune system can affect the risk of developing Merkel cell carcinoma.</p><p>&nbsp;</p><p>If you experience any of these,<strong> tell your doctor straight away</strong>.</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very common</strong> (may affect more than 1 in 10 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection from flu virus with symptoms such as tiredness, chills, sore throat, aching in the joints</p><p>or muscles, fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling of pressure or pain in the cheeks and forehead (sinusitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood testing showing higher levels of liver enzymes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ringworm, a fungal infection of the skin (tinea versicolor)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe headache often accompanied by nausea, vomiting and sensitivity to light (migraine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of white blood cells (lymphocytes, leucocytes)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weakness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itchy, red, burning rash (eczema)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood fat (triglycerides) level increased</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathlessness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision (see also the section on macular oedema under &ldquo;Some side effects could be or could become serious&rdquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension (Golimara may cause a mild increase in blood pressure.)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of certain white blood cells (neutrophils)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depressed mood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect up to 1 in 1,000 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood vessel disorders</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nervous system disorders</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cancer of the lymphatic system (lymphoma)</p><p>&nbsp;</p><p><strong>Not known</strong> (frequency cannot be estimated from the available data):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peripheral swelling</p><p>&nbsp;</p><p>If any of these affects you severely, <strong>tell your doctor</strong>.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&deg; C.</p><p>&nbsp;</p><p>Do not use this medicine if you notice that the pack is damaged or shows signs of tampering.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is fingolimod.</p><p>Each hard capsule contains 0.5 mg fingolimod (as hydrochloride).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>Capsule fill: tricalcium phosphate, stearic acid 50</p><p>Capsule shell: gelatin, titanium dioxide (E171), iron oxide yellow (E172).</p><p>Printing ink:<em> </em>shellac, iron oxide black (E172).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Golimara 0.5 mg hard capsules are presented as white to off-white powder in a yellow opaque cap and white opaque body size No 3 hard gelatin capsule with length 15.9 ± 0.3 mm, imprinted with “0.5 mg” on the cap with black ink.
	
Golimara 0.5 mg hard capsules are packaged in a cardboard box containing the appropriate number of PVC/PE/PVDC aluminium foil blisters with an appropriate number of capsules and an instruction leaflet. 
	
	Pack sizes:
	Cartons containing 28 or 98 hard capsules.
	
	Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufacturer:</p><p><strong>PHARMATHEN INTERNATIONAL S.A.</strong></p><p>Industrial Park Sapes,</p><p>Ropodi Prefecture,</p><p>Block No 5, Rodopi 69300</p><p>Greece<br />&nbsp;</p><p>Marketing Authorization Holder &amp; Secondary Packaging:</p><p><strong>SPIMACO</strong></p><p>Al-Qassim Pharmaceutical Plant</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2022.                                    
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>&nbsp;</strong></p><p><strong>ما هو جوليمارا:</strong> المادة الفعالة في مستحضر جوليمارا هى فينجوليمود.</p><p dir="RTL"><strong>فيم يستخدم جوليمارا:</strong></p><p dir="RTL">جوليمارا يستخدم في البالغين والأطفال والمراهقين (10 سنوات من العمر فما فوق) لعلاج انتكاس التصلب العصبي المتعدد الناجم عن مرض التصلب العصبي المتعدد (MS)، وبشكل أكثر تحديداً في:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى الذين فشلوا في الاستجابة على الرغم من خضوعهم لعلاج مرض التصلب العصبي المتعدد.</p><p dir="RTL">أو</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى الذين تطورت لديهم بسرعة شدة أعراض مرض التصلب العصبي المتعدد.</p><p dir="RTL">جوليمارا لا يسبب الشفاء من مرض التصلب العصبي المتعدد، لكنه يساعد على إنقاص عدد الانتكاسات والحد من تطور الإعاقة الجسدية بسبب مرض التصلب العصبي المتعدد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هو مرض التصلب العصبى المتعدد</strong></p><p dir="RTL">مرض التصلب العصبي المتعدد هو حالة طويلة الأجل تؤثر على الجهاز العصبي المركزي، ويتألف من المخ و</p><p dir="RTL">الحبل الشوكي. يسبب مرض التصلب العصبي المتعدد التهاباً يدمر الغشاء الواقى (يسمى المايلين) حول الأعصاب في</p><p dir="RTL">الجهاز العصبي المركزي وتوقف الأعصاب عن العمل بشكل صحيح. وهذا ما يسمى إزالة الميالين.</p><p dir="RTL">يتميز مرض التصلب العصبي المتعدد بعدد من الهجمات المتكررة (الانتكاسات) لأعراض الجهاز العصبي</p><p dir="RTL">التي تعكس وجود التهاب داخل الجهاز العصبي المركزي. تختلف الأعراض من مريض لآخر ولكنها عادةً ما تتضمن</p><p dir="RTL">صعوبات فى المشي، أو تنميل، أو مشاكل في الرؤية، أو اضطراب فى التوازن. أعراض الانتكاس قد</p><p dir="RTL">تختفي تماماً عند انتهاء الانتكاس، ولكن قد تظل هناك بعض المشكلات.</p><p dir="RTL"><strong>كيفية عمل جوليمارا</strong></p><p dir="RTL">يساعد جوليمارا على حماية الجهاز العصبى المركزى من الهجمات التي يتعرض لها عبر الجهاز المناعي عن طريق تقليل قدرة بعض خلايا الدم البيضاء (الخلايا اللمفاوية) على التحرك بحرية داخل الجسم ومنعها من الوصول إلى المخ والحبل الشوكي. مما يؤدي إلى الحد من تلف الأعصاب الناجم عن مرض التصلب العصبي المتعدد. جوليمارا يقلل أيضاً من بعض ردود الفعل المناعية لجسمك.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تقم بتناول جوليمارا فى الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك استجابة مناعية منخفضة (بسبب متلازمة نقص المناعة أو بسبب مرض أو بسبب تناول بعض الأدوية التي تقمع الجهاز المناعي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك عدوى نشطة شديدة أو عدوى مزمنة نشطة مثل التهاب الكبد أو السل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من سرطان نشط.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل حادة في الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تعرضت خلال الستة أشهر الماضية لنوبة قلبية أو ذبحة صدرية أو سكتة دماغية أو تحذير من حدوث سكتة دماغية أو أنواع معينة من فشل القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أنواع معينة من عدم انتظام ضربات القلب أو وجود اضطراب فى ضربات القلب، بما في ذلك المرضى</p><p dir="RTL">الذين يظهر لديهم إطالة في فترة QT عند إجراء تخطيط القلب الكهربائى (ECG) قبل البدء فى تناول جوليمارا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أو تناولت مؤخراً أدوية لعلاج عدم انتظام ضربات القلب مثل كينيدين، أو ديسوبيراميد، أو أميودارون أو سوتالول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه مادة فينجوليمود أو أي من المكونات الأخرى لهذا الدواء (المذكورة في الفقرة رقم 6).</p><p dir="RTL">فى حالة انطباق أى مما سبق ذكره عليك، أخبر طبيبك المعالج أو الصيدلى قبل البدء فى تناول جوليمارا.</p><p dir="RTL"><strong>المحاذير والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك المعالج قبل تناول جوليمارا فى الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل شديدة في التنفس أثناء النوم (ضيق شديد فى التنفس أثناء النوم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك خلل فى تخطيط القلب الكهربائي الخاص بك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أعراض بطء معدل ضربات القلب (مثل الدوخة والغثيان أو الخفقان).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أو تناولت مؤخراً أدوية تبطئ من معدل ضربات القلب (مثل حاصرات بيتا، أو فيراباميل، أو ديلتيازيم أو إيفابرادين، أو ديجوكسين، أو مضادات الكولين أو بيلوكاربين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ من فقدان الوعي المفاجئ أو الإغماء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخطط للتطعيم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تكن قد أصبت بجدري الماء من قبل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطرابات بصرية أو لديك علامات تورم أخرى في منطقة الرؤية المركزية في الجزء الخلفي من العين (حالة تعرف باسم وذمة البقعة الصفراء، انظر أدناه)، أو التهاب أو عدوى فى العين (التهاب القزحية) أو إذا كنت تعاني من مرض السكر (والذي يمكن أن يسبب مشاكل في العين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ارتفاع في ضغط الدم لا يمكن التحكم فيه عن طريق الأدوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل شديدة في الرئة أو سعال نتيجة التدخين.</p><p dir="RTL">فى حالة انطباق أى مما سبق ذكره عليك، أخبر طبيبك المعالج أو الصيدلى قبل البدء فى تناول جوليمارا.</p><p dir="RTL"><u>تباطؤ معدل ضربات القلب وعدم انتظام ضربات القلب</u></p><p dir="RTL">في بداية العلاج، جوليمارا قد يسبب إبطاء فى معدل ضربات القلب. نتيجة لذلك، قد تشعر بالدوار أو التعب أو تشعر حسياً بدقات قلبك أو قد ينخفض ضغط الدم لديك. إذا كانت هذه الآثار واضحة، أخبر طبيبك المعالج، لأنك قد تحتاج إلى علاج على الفور. جوليمارا يمكن أن يسبب أيضاً عدم انتظام ضربات القلب، وخاصةً بعد الجرعة الأولى. عادةً ما يعود نبض القلب غير المنتظم إلى طبيعته في أقل من يوم واحد. عادةً ما يعود معدل ضربات القلب البطيء إلى طبيعته خلال شهر واحد.</p><p dir="RTL">سوف يطلب منك طبيبك المعالج البقاء فى غرفة الجراحة أو العيادة لمدة 6 ساعات على الأقل، لفحص النبض وضغط الدم لديك كل ساعة، بعد تناول الجرعة الأولى من جوليمارا بحيث يمكن اتخاذ التدابير المناسبة في حالة حدوث أعراض جانبية في بداية العلاج. يجب أن يكون لديك رسم القلب قبل الجرعة الأولى من جوليمارا وبعد فترة المراقبة لمدة 6 ساعات. قد يراقب طبيبك رسم القلب بشكل مستمر خلال ذلك الوقت. إذا كان لديك تباطؤ شديد أو نقص فى معدل ضربات القلب بعد فترة 6 ساعات، أو إذا ظهر خللاً فى تخطيط القلب الخاص بك، فقد تحتاج إلى إجراء مراقبته لفترة أطول (ساعتان إضافيتان على الأقل وربما طوال الليل) حتى يتم زوال تلك الأعراض. قد ينطبق الشيء نفسه إذا كنت تستأنف جوليمارا بعد فترة انقطاع عن العلاج، وهذا يتوقف على كل من فترة الانقطاع عن العلاج وطول المدة التي كنت تتناول فيها جوليمارا قبل الانقطاع عن العلاج.&nbsp;</p><p dir="RTL">إذا كان لديك، أو إذا كنت فى خطر التعرض إلى، وجود خلل أو عدم انتظام فى ضربات القلب، أو لديك خلل فى تخطيط القلب الكهربائي، أو إذا كان لديك مرض بالقلب أو فشل بالقلب، فقد يكون جوليمارا غير مناسباً لك.</p><p dir="RTL">إذا كان لديك تاريخ من فقدان الوعي المفاجئ أو انخفاض معدل ضربات القلب، فقد لا يكون جوليمارا مناسباً لك. سيتم تقييمك بواسطة أخصائي أمراض القلب لتقديم المشورة حول كيفية البدء في العلاج باستخدام جوليمارا، بما في ذلك المراقبة الليلية.</p><p dir="RTL">إذا كنت تتناول أدوية قد تسبب انخفاضاً فى معدل ضربات القلب، فقد لا يكون جوليمارا مناسباً لك. سوف تحتاج إلى تقييم من قبل أخصائي أمراض القلب، والذي سيتحقق من إمكانية تحويلك إلى الطب البديل الذي لا يقلل من معدل ضربات القلب من أجل السماح للعلاج بواسطة جوليمارا. فى حال استحالة وجود البديل، فسوف ينصح أخصائي أمراض القلب بالطريقة التي يجب أن تبدأ بها العلاج بواسطة جوليمارا، بما في ذلك المراقبة الليلية.</p><p dir="RTL"><u>إذا لم تكن قد أصبت بجدري الماء من قبل</u></p><p dir="RTL">إذا لم تكن قد أصبت بجدري الماء من قبل، فسوف يفحص طبيبك مناعتك ضد الفيروس الذي يسببه (فيروس الحماق النطاقي). إذا لم تكن محمياً ضد الفيروس، فقد تحتاج إلى تطعيم قبل بدء العلاج بواسطة جوليمارا. إذا كانت هذه هي الحالة، فسوف يؤخر طبيبك بدء العلاج بواسطة جوليمارا حتى شهر واحد بعد اكتمال عملية التطعيم بشكل كامل.</p><p dir="RTL"><u>العدوى</u></p><p dir="RTL">جوليمارا يخفض عدد خلايا الدم البيضاء (وخاصة عدد الخلايا اللمفاوية). تحارب خلايا الدم البيضاء العدوى. أثناء تناولك جوليمارا (ولمدة تصل إلى شهرين بعد التوقف عن تناوله)، قد تصاب بالعدوى بسهولة أكبر. أي عدوى لديك بالفعل قد تزداد سوءً. العدوى يمكن أن تكون خطيرة وتهدد الحياة. إذا كنت تعتقد أن لديك عدوى، أو حمى، أو تشعر بأنك مصاب بالأنفلونزا أو لديك صداع مصحوب بتصلب فى الرقبة، أو حساسية للضوء، أو غثيان، و / أو ارتباك (قد يكون سببها عدوى فطرية وقد تكون أعراض التهاب السحايا)، اتصل بطبيبك المعالج على الفور، لأنه قد يكون خطيراً ويهدد الحياة. إذا كنت تعتقد أن مرض التصلب العصبي المتعدد يزداد سوءً (على سبيل المثال الضعف أو التغيرات البصرية) أو إذا لاحظت أي أعراض جديدة، فتحدث إلى طبيبك المعالج على الفور، لأن هذه قد تكون أعراض اضطراب نادرة في المخ بسبب العدوى وتسمى اعتلال المخ التقدمي متعدد البؤر (PML) وهي حالة خطيرة قد تؤدي إلى إعاقة شديدة أو وفاة.</p><p dir="RTL">تم الإبلاغ عن الإصابة بفيروس الورم الحليمي البشري (HPV)، وتشمل الورم الحليمي، خلل التنسج، الثآليل والسرطان المرتبط بفيروس الورم الحليمي البشري، في المرضى الخاضعين للعلاج بواسطة فينجوليمود. سوف يفكر طبيبك المعالج فيما إذا كنت بحاجة إلى تطعيم ضد فيروس الورم الحليمي البشري قبل بدء العلاج. إذا كنتِ امرأة، سيوصي طبيبك المعالج أيضاً بفحص فيروس الورم الحليمي البشري.</p><p dir="RTL"><u>وذمة البقعة الصفراء</u></p><p dir="RTL">قبل أن تبدأ فى تناول جوليمارا، إذا كنت تعاني من اضطرابات بصرية أو علامات تورم أخرى في منطقة الرؤية المركزية في الجزء الخلفي من العين، أو التهاب أو عدوى فى العين (التهاب القزحية) أو مرض السكر، فقد يرغب طبيبك المعالج فى إجراء فحص عينيك.</p><p dir="RTL">قد يطلب منك طبيبك المعالج إجراء فحص للعين خلال 3 إلى 4 أشهر بعد بداية العلاج بواسطة جوليمارا.</p><p dir="RTL">البقعة هي منطقة صغيرة من شبكية العين في الجزء الخلفي من العين والتي تمكنك من رؤية الأشكال والألوان والتفاصيل بوضوح وبشكل حاد. جوليمارا قد يسبب تورم في البقعة، وهي حالة تعرف باسم وذمة البقعة الصفراء. يحدث التورم عادةً في الأشهر الأربعة الأولى من فترة العلاج بواسطة جوليمارا.</p><p dir="RTL">فرصتك للتعرض إلى حدوث الوذمة البقعية تزداد إذا كنت تعاني من مرض السكر أو إذا كنت مصاباً بمرض التهاب بالعين يسمى التهاب القزحية. في هذه الحالات سيرغب طبيبك المعالج في إجراء فحوصات لعينيك بشكل منتظم للكشف عن وذمة البقعة الصفراء.</p><p dir="RTL">إذا كنت تعاني من الوذمة البقعية، فتحدث إلى طبيبك المعالج قبل أن تستأنف العلاج باستخدام جوليمارا.</p><p dir="RTL">يمكن أن تسبب الوذمة البقعية بعض الأعراض الخاصة بالرؤية والتى تشبه تلك الخاصة بنوبة التصلب العصبي المتعدد (التهاب العصب البصري). في وقت مبكر، قد لا يكون هناك أي أعراض. تأكد من إخبار طبيبك المعالج عن أي تغييرات في رؤيتك. قد يرغب طبيبك المعالج فى إجراء فحوصات لعينيك، خاصةً إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان هناك ضبابية أو ظلال فى مركز الرؤية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرضت لوجود بقعة عمياء في مركز رؤيتك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك مشاكل في رؤية الألوان أو التفاصيل الدقيقة.</p><p dir="RTL"><u>اختبارات وظائف الكبد</u></p><p dir="RTL">إذا كنت تعاني من مشاكل حادة في الكبد، يجب ألا تتناول جوليمارا. قد يؤثر جوليمارا على وظائف الكبد. من المحتمل ألا تلاحظ أي أعراض، لكن إذا لاحظت اصفرار جلدك أو اصفرار بياض عينيك، أو بول غامق بشكل غير طبيعي أو غثيان وقيء بدون سبب، أخبر طبيبك المعالج على الفور.</p><p dir="RTL">إذا شعرت بأي من هذه الأعراض بعد بدء تناول جوليمارا، أخبر طبيبك المعالج على الفور.</p><p dir="RTL">خلال الأشهر الإثني عشر الأولى من العلاج، سيطلب طبيبك المعالج إجراء اختبارات دم لمراقبة وظائف الكبد. إذا كانت نتائج الاختبار تشير إلى وجود مشكلة في الكبد، فقد تضطر إلى إيقاف العلاج بواسطة جوليمارا.</p><p dir="RTL"><u>ارتفاع ضغط الدم </u></p><p dir="RTL">نظرًا لأن جوليمارا يسبب ارتفاعاً طفيفاً في ضغط الدم، فقد يرغب طبيبك المعالج في فحص ضغط الدم لديك بانتظام.</p><p dir="RTL"><u>مشاكل الرئة</u></p><p dir="RTL">جوليمارا له تأثير طفيف على وظيفة الرئة. قد يكون لدى المرضى الذين يعانون من مشاكل حادة بالرئة أو لديهم سعال نتيجة التدخين فرصة أكبر للإصابة بأعراض جانبية.</p><p dir="RTL"><u>تعداد الدم</u></p><p dir="RTL">التأثير المطلوب لعلاج جوليمارا هو تقليل كمية خلايا الدم البيضاء في دمك. هذا عادةً ما يعود إلى طبيعته خلال شهرين من التوقف عن العلاج. إذا كنت بحاجة إلى إجراء أي اختبارات دم، أخبر الطبيب المعالج بأنك تتناول جوليمارا. خلاف ذلك، قد لا يكون من الممكن للطبيب أن يفهم نتائج الاختبار وفى أنواع معينة من اختبار الدم قد يحتاج طبيبك المعالج إلى أخذ المزيد من الدم بشكل أكثر من المعتاد.</p><p dir="RTL">قبل أن تبدأ فى تناول جوليمارا، سيؤكد طبيبك المعالج ما إذا كان لديك ما يكفي من خلايا الدم البيضاء في دمك وقد ترغب في تكرار الفحص بانتظام. في حال لم يكن لديك ما يكفي من خلايا الدم البيضاء، قد تضطر إلى إيقاف العلاج بواسطة جوليمارا.</p><p dir="RTL"><u>متلازمة اعتلال المخ العكسي الخلفي (</u><u>PRES</u><u>)</u></p><p dir="RTL">نادراً ما تم الإبلاغ عن حالة تسمى متلازمة اعتلال المخ العكسي الخلفي (PRES) لدى مرضى التصلب العصبي المتعدد الخاضعين للعلاج بواسطة فينجوليمود. قد تشمل الأعراض ظهور مفاجئ لصداع شديد، ارتباك، نوبات صرع وتغير فى الرؤية. أخبر طبيبك المعالج على الفور إذا كنت تواجه أي من هذه الأعراض أثناء علاجك بواسطة جوليمارا، لأنه قد يكون خطيراً.</p><p dir="RTL"><u>سرطان الجلد</u></p><p dir="RTL">تم الإبلاغ عن سرطان الجلد في مرضى التصلب العصبي المتعدد الخاضعين للعلاج بواسطة فينجوليمود. تحدث إلى طبيبك المعالج على الفور إذا لاحظت أي عقيدات جلدية (مثل عقيدات لامعة) أو بقع أو تقرحات مفتوحة لا تلتئم خلال أسابيع. قد تتضمن أعراض سرطان الجلد نمواً غير طبيعياً أو تغيرات في أنسجة الجلد (مثل الشامات غير العادية) مع تغير اللون أو الشكل أو الحجم مع مرور الوقت. قبل أن تبدأ فى تناول جوليمارا، يجب إجراء فحص للجلد للتحقق مما إذا كان لديك أي عقيدات جلدية. سيقوم طبيبك المعالج أيضاً بإجراء فحوصات جلدية بشكل منتظم أثناء علاجك بجوليمارا. إذا كنت تعاني من مشاكل في بشرتك، فقد يحولك طبيبك المعالج إلى طبيب أمراض جلدية، والذي قد يقرر بعد التشاور أنه من المهم أن يتم رؤيتك بشكل منتظم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التعرض لآشعة الشمس والحماية من أشعة الشمس</u></p><p dir="RTL">فينجوليمود يضعف نظام المناعة لديك.</p><p dir="RTL">مما يزيد من خطر الإصابة بالسرطان، خاصةً سرطان الجلد. يجب عليك الحد من التعرض لآشعة الشمس والآشعة فوق البنفسجية عن طريق:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتداء ملابس واقية مناسبة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدام مستحضرات واقية من الشمس ذات درجة عالية من الحماية من الآشعة فوق البنفسجية بشكل منتظم.</p><p dir="RTL"><u>كبار السن</u></p><p dir="RTL">المعلومات بشأن استخدام جوليمارا في المرضى المسنين (أكثر من 65 سنة) محدودة. تحدث إلى طبيبك المعالج إذا كانت لديك أي مخاوف.</p><p dir="RTL"><u>الأطفال والمراهقين</u></p><p dir="RTL">لا يستخدم هذا الدواء للأطفال دون سن 10 سنوات لأنه لم تتم دراسته في مرضى التصلب المتعدد في هذه الفئة العمرية.</p><p dir="RTL">تنطبق التحذيرات والاحتياطات المذكورة أعلاه أيضاً على الأطفال والمراهقين. المعلومات التالية مهمة بشكل خاص للأطفال والمراهقين ومقدمي الرعاية لهم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل أن تبدأ فى تناول جوليمارا، سيفحص طبيبك المعالج حالة التطعيم لديك. إذا لم تكن قد تلقيت بعض التطعيمات، فقد يكون من الضروري إعطاؤك هذه التطعيمات قبل البدء فى العلاج بواسطة جوليمارا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في المرة الأولى التي تتناول فيها جوليمارا، سيقوم طبيبك المعالج بمراقبة معدل ضربات القلب ونبضات القلب (راجع فقرة &quot; تباطؤ معدل ضربات القلب وعدم انتظام ضربات القلب&quot; الموضحة أعلاه).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تشنجات أو نوبات قبل أو أثناء تناول جوليمارا، أخبر طبيبك المعالج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الاكتئاب أو القلق قبل البدء فى تناول جوليمارا أو إذا أصبت بالاكتئاب أو القلق أثناء تناولك جوليمارا، فأخبر طبيبك المعالج. فقد تحتاج إلى المزيد من المراقبة عن قرب.</p><p dir="RTL"><strong>استخدام جوليمارا والأدوية الأخرى </strong></p><p dir="RTL">أخبر طبيبك المعالج أو الصيدلي إذا كنت تتناول، أو قد تناولت مؤخراً أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">أخبر طبيبك المعالج إذا كنت تتناول أياً من الأدوية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تعمل على قمع أو تعديل استجابة الجهاز المناعي، بما في ذلك الأدوية الأخرى المستخدمة لعلاج مرض التصلب العصبي المتعدد، مثل بيتا إنترفيرون، جلاتيرامير أسيتات، ناتاليزوماب، ميتوزانترون، تيريفلونومايد، ثنائي ميثيل فيومارات أو أليمتوزوماب. يجب عدم استخدام جوليمارا بالتزامن مع مثل هذه الأدوية حيث قد يؤدي ذلك إلى تكثيف التأثير على الجهاز المناعي (انظر أيضاً فقرة &quot; لا تقم بتناول جوليمارا فى الحالات الآتية&quot;).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستيرويدات، بسبب التأثير الإضافي المحتمل على الجهاز المناعي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التطعيمات. إذا كنت بحاجة إلى تلقي تطعيم، فاطلب نصيحة طبيبك المعالج أولاً. أثناء فترة العلاج بواسطة جوليمارا وما يصل إلى شهرين بعد العلاج باستخدام جوليمارا، يجب ألا تتلقى أنواعاً معينة من التطعيمات (مثل التطعيمات الحية)، لأنها يمكن أن تؤدي إلى الإصابة التي كان من المفترض أن تمنعها. قد لا تعمل التطعيمات الأخرى بالطريقة المعتادة إذا تم تناولها خلال هذه الفترة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تبطئ نبضات القلب (على سبيل المثال حاصرات بيتا، مثل أتينولول). قد يؤدي استخدام جوليمارا مع هذه الأدوية إلى تكثيف التأثير على دقات القلب في الأيام الأولى بعد بدء العلاج بواسطة جوليمارا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج عدم انتظام ضربات القلب، مثل كينيدين أو ديسوبيراميد أو أميودارون أو سوتالول. يجب عدم استخدام جوليمارا، إذا كنت تستخدم مثل هذه الأدوية حيث قد يزيد ذلك من التأثير على عدم انتظام ضربات القلب (انظر أيضاً فقرة &quot; لا تقم بتناول جوليمارا فى الحالات الآتية&quot;).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أدوية أخرى:</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات الإنزيم البروتيني، مضادات الفطريات مثل كيتوكونازول، مضادات الفطريات من مجموعة الآزول، كلاريثروميسين أو تليثروميسين.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين، ريفامبيسين، فينوباربيتال، فينيتوين، إيفافايرينز أو نبتة سانت جون (وذلك لوجود خطر محتمل لتقليل فعالية جوليمارا).</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو ترضعين طفلك طبيعياً، أو إذا كنتِ تعتقدين بأنكِ حامل أو تخططين لإنجاب طفل، اسألى طبيبك المعالج للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">قبل أن تبدئى فى العلاج بواسطة جوليمارا، قد يطلب منك طبيبك المعالج إجراء اختبار الحمل للتأكد من عدم وجود حمل. يجب تجنب الحمل أثناء فترة العلاج بواسطة جوليمارا أو في الشهرين التاليين بعد التوقف عن تناوله، لأن هناك خطر حدوث ضرر للطفل. تحدث مع طبيبك المعالج بشأن الطرق الموثوقة لتحديد النسل والتي يجب عليكِ استخدامها أثناء العلاج ولمدة شهرين بعد توقف العلاج.</p><p dir="RTL">إذا أصبحت حاملاً أثناء تناول جوليمارا، فيجب التوقف عن تناول الدواء وإبلاغ طبيبك المعالج على الفور. ليتم اتخاذ قرار ما بينك وبين طبيبك المعالج ما هو الأفضل لك ولطفلك.</p><p dir="RTL">يجب عدم الإرضاع طبيعياً أثناء العلاج بواسطة جوليمارا. حيث قد ينتقل جوليمارا إلى حليب الثدي مما قد يؤدى إلى خطر حدوث آثار جانبية خطيرة على الطفل.</p><p dir="RTL">اسألى طبيبك المعالج أو الصيدلي للحصول على المشورة قبل تناول أي دواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">سيخبرك طبيبك المعالج ما إذا كانت حالتك المرضية تؤهلك لقيادة المركبات، بما في ذلك الدراجة، واستخدام الآلات بأمان. ليس من المتوقع أن يكون جوليمارا ذو تأثير على قدرتك على القيادة واستخدام الآلات.</p><p dir="RTL">ومع ذلك، عند بدء العلاج، يجب عليك البقاء في غرفة الطبيب أو العيادة لمدة 6 ساعات بعد تناول الجرعة الأولى من جوليمارا. قد تتأثر قدرتك على القيادة واستخدام الآلات خلال هذه الفترة الزمنية وربما بعدها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم الإشراف على العلاج باستخدام جوليمارا من قبل طبيب من ذوي الخبرة في علاج مرض التصلب المتعدد.</p><p dir="RTL">قم دائماً بتناول هذا الدواء تماماً كما أخبرك طبيبك المعالج. استشِر طبيبك المعالج إذا لم تكن متأكداً.</p><p dir="RTL"><strong>الاستخدام في البالغين</strong></p><p dir="RTL">الجرعة الموصى بها هي كبسولة واحدة في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين (10 سنوات من العمر وما فوق)</strong></p><p dir="RTL"><strong>تعتمد الجرعة على وزن الجسم:</strong></p><p dir="RTL">الجرعة الموصى بها هي كبسولة واحدة يومياً للأطفال والمراهقين الذين تزيد أوزانهم عن 40 كجم.</p><p dir="RTL">لا تتجاوز الجرعة الموصى بها.</p><p dir="RTL">جوليمارا هو للاستخدام عن طريق الفم.</p><p dir="RTL">قم بتناول جوليمارا مرة واحدة في اليوم مع كوب من الماء. يجب دائماً ابتلاع كبسولة جوليمارا سليمة، دون فتحها. يمكن تناول جوليمارا مع أو بدون الطعام.</p><p dir="RTL">قم بتناول جوليمارا في نفس الوقت كل يوم فسوف يساعدك ذلك على تذكر وقت تناول الدواء.</p><p dir="RTL">قد يحولك طبيبك المعالج مباشرة من بيتا إنترفيرون أو جلاتيرامير أسيتات أو ثنائي ميثيل فيومارات إلى جوليمارا، إذا لم تكن هناك علامات على وجود اضطرابات ناتجة عن العلاج السابق. قد يتعين على طبيبك المعالج إجراء فحص دم لاستبعاد مثل هذه الاضطرابات. بعد إيقاف ناتاليزوماب قد تضطر إلى الانتظار لمدة 2-3 أشهر قبل بدء العلاج بواسطة جوليمارا. للتبديل من تيريفلونومايد، قد ينصحك طبيبك المعالج بالانتظار لفترة معينة أو للذهاب إلى إجراء آخر لتسريع عملية التبديل. إذا تم علاجك بـواسطة أليمتوزوماب، فيجب إجراء تقييم شامل ومناقشة الأمر مع طبيبك المعالج لتحديد ما إذا كان جوليمارا مناسباً لك.</p><p dir="RTL">إذا كانت لديك أسئلة بشأن مدة العلاج بواسطة جوليمارا، فتحدث إلى طبيبك المعالج أو الصيدلي.</p><p dir="RTL"><strong>إذا تناولت جوليمارا أكثر مما ينبغى</strong></p><p dir="RTL">إذا كنت قد تناولت الكثير من جوليمارا، فاتصل بطبيبك المعالج على الفور.</p><p dir="RTL"><strong>إذا نسيت أن تتناول جوليمارا</strong></p><p dir="RTL">إذا كنت تخضع للعلاج بواسطة جوليمارا لمدة تقل عن شهر واحد ونسيت تناول جرعة واحدة ليوم كامل، فاتصل بطبيبك المعالج قبل تناول الجرعة التالية. فقد يقرر طبيبك المعالج إبقائك تحت الملاحظة في الوقت الذي تتناول فيه الجرعة التالية.</p><p dir="RTL">إذا كنت تتناول جوليمارا لمدة شهر واحد على الأقل ونسيت تناول علاجك لأكثر من أسبوعين، فاتصل بطبيبك المعالج قبل تناول الجرعة التالية. فقد يقرر طبيبك إبقائك تحت الملاحظة في الوقت الذي تتناول فيه الجرعة التالية. ومع ذلك، إذا نسيت تناول الجرعات الخاصة بك من جوليمارا لمدة تصل إلى أسبوعين، &nbsp;فيمكنك تناول الجرعة التالية كما هو مخطط لها.</p><p dir="RTL">لا تقم بمضاعفة الجرعة لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>إذا توقفت عن تناول جوليمارا</strong></p><p dir="RTL">لا تتوقف عن تناول جوليمارا أو تغيير الجرعة دون التحدث إلى طبيبك المعالج أولاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيبقى جوليمارا في جسمك لمدة تصل إلى شهرين بعد التوقف عن تناوله. قد يظل عدد خلايا الدم البيضاء (عدد الخلايا اللمفاوية) منخفضاً أيضاً خلال هذا الوقت وقد تستمر الأعراض الجانبية الموضحة في هذه النشرة. بعد إيقاف جوليمارا، قد تضطر إلى الانتظار لمدة 6-8 أسابيع قبل بدء علاج جديد لمرض التصلب العصبي المتعدد.</p><p dir="RTL">إذا اضطررت إلى الرجوع مرة أخرى للعلاج بواسطة جوليمارا بعد أكثر من أسبوعين من التوقف عن تناوله، فقد يحدث التأثير على معدل ضربات القلب الذي يظهر عادةً عند بدء العلاج لأول مرة، وسوف تحتاج إلى مراقبته في عيادة الطبيب لإعادة بدء العلاج مرة أخرى. لا تقم بالرجوع إلى العلاج بواسطة جوليمارا بعد إيقافه لأكثر من أسبوعين دون طلب المشورة من طبيبك المعالج.</p><p dir="RTL">سيقرر طبيبك المعالج مدى وكيفية احتياجك للمراقبة بعد التوقف عن العلاج بواسطة جوليمارا.</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية بشأن استخدام هذا الدواء، اسأل طبيبك المعالج أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية قد يسبب هذا الدواء أعراضاً جانبية وإن لم تكن تحدث لكل من يتناول هذا الدواء.</p><p dir="RTL">بعض الأعراض الجانبية قد تكون أو قد تصبح خطيرة.</p><p dir="RTL">أعراض جانبية شائعة (والتى قد تصيب ما يصل إلى 1 لكل 10 أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال مع مخاط، عدم راحة بالصدر، حمى (وهي علامات لوجود اضطراب بالرئة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فيروس الهربس (القوباء المنطقية أو الهربس النطاقي) مع أعراض مثل تقرحات، وحرق، حكة أو ألم في الجلد، عادةً على الجزء العلوي من الجسم أو الوجه. قد تكون الأعراض الأخرى هى حمى وضعف كالمراحل المبكرة من الإصابة بعدوى، تليها خدر أو حكة أو بقع حمراء مع ألم شديد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء نبضات القلب (بطء القلب)، مع عدم انتظام ضربات القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من سرطان الجلد يسمى سرطان الخلايا القاعدية (BCC) والذي يظهر غالباً كأنه عقيدات لؤلؤية، على الرغم من أنها يمكن أن تتخذ أشكالاً أخرى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المعروف زيادة معدل تكرار الاكتئاب والقلق عند مرضى التصلب العصبي المتعدد كما تم الإبلاغ عن ذلك في الأطفال والمراهقين الذين تم علاجهم بواسطة فينجوليمود.</p><p dir="RTL">أعراض جانبية غير شائعة (والتى قد تصيب ما يصل إلى 1 لكل 100 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب رئوي مع أعراض مثل الحمى والسعال وصعوبة التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وذمة البقعة الصفراء (وهي تورم في منطقة الرؤية المركزية للشبكية في الجزء الخلفي من العين) مع أعراض مثل وجود ظلال أو بقعة عمياء في مركز الرؤية، أو عدم وضوح الرؤية، أو مشاكل فى رؤية الألوان أو التفاصيل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الصفائح الدموية مما يزيد من خطر النزيف أو الكدمات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجلد الخبيث (نوع من سرطان الجلد الذي عادةً ما يتطور من شامة غير عادية). تشمل العلامات المحتملة لسرطان الجلد وجود شامات متغيرة الحجم أو الشكل أو الارتفاع أو اللون مع مرور الوقت أو ظهور شامات جديدة. قد تكون الشامات مصحوبة بحكة، أو نزف أو تقرح.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج، نوبات (أكثر تكراراً في الأطفال والمراهقين من البالغين).</p><p dir="RTL">أعراض جانبية نادرة (والتى قد تصيب ما يصل إلى 1 لكل 1000 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة تسمى متلازمة اعتلال المخ العكسي الخلفي (PRES). قد تشمل الأعراض حدوث مفاجئ لصداع شديد، وارتباك، ونوبات و / أو اضطرابات فى الرؤية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الغدد الليمفاوية (نوع من السرطان يصيب الجهاز اللمفاوي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الخلايا الحرشفية: نوع من سرطان الجلد الذي قد يظهر كعقدة حمراء صلبة، أو قرحة مع قشرة أو قرحة جديدة على ندبة موجودة.</p><p dir="RTL">أعراض جانبية نادرة جداً (والتى قد تصيب ما يصل إلى 1 لكل 10،000 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل فى تخطيط القلب الكهربائى (انعكاس الموجة T)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ورم مرتبط بالعدوى بفيروس الهربس البشري 8 (كابوسي ساركوما).</p><p dir="RTL">أعراض جانبية غير معروفة (لا يمكن تقدير معدل تكرارها من خلال البيانات المتاحة):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تحسسية، بما في ذلك أعراض الطفح الجلدي أو الحكة، أو تورم في الشفاه واللسان أو الوجه، والتي من المرجح أن تحدث في اليوم الذي تبدأ فيه العلاج بواسطة جوليمارا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خطر حدوث عدوى نادرة في المخ تسمى اعتلال المخ التقدمي المتعدد البؤر (PML). قد تتشابه أعراض اعتلال المخ التقدمي المتعدد البؤر مع أعراض انتكاس مرض التصلب العصبي المتعدد. قد تظهر الأعراض أيضاً لديك ولا تستطيع إدراكها بنفسك، مثل التغيرات في الحالة المزاجية أو السلوك، أو فقدان الذاكرة، أو صعوبات النطق والتواصل، والتي قد تحتاج لمزيد من البحث من قبل طبيبك المعالج لاستبعاد اعتلال المخ التقدمي المتعدد البؤر. لذلك، إذا كنت تعتقد أن مرض التصلب العصبي المتعدد الخاص بك يزداد سوءً أو إذا لاحظت أنت أو المقربون منك أي أعراض جديدة أو غير عادية، فمن المهم للغاية أن تتحدث إلى طبيبك المعالج في أقرب وقت ممكن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات المكورات العقدية (نوع من العدوى الفطرية)، بما في ذلك التهاب السحايا بالمكورات العقدية مع وجود أعراض مثل الصداع المصحوب بتصلب شديد فى الرقبة، وحساسية للضوء والغثيان و / أو ارتباك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان خلايا ميركل (نوع من سرطان الجلد). العلامات المحتملة لسرطان خلايا ميركل تشمل عقيدة بلون اللحم أو أحمر مزرق، غير مؤلمة، غالباً على الوجه أو الرأس أو الرقبة. سرطان خلايا ميركل يمكن أن يظهر أيضاً كعقدة أو كتلة غير مؤلمة. التعرض لفترة طويلة لآشعة الشمس مع ضعف فى الجهاز المناعى قد يؤثر على خطر الإصابة بسرطان خلايا ميركل.</p><p dir="RTL">إذا تعرضت لأي مما سبق ذكره، أخبر طبيبك المعالج فوراً.</p><p dir="RTL"><strong>أعراض جانبية أخرى</strong></p><p dir="RTL">أعراض جانبية شائعة جداً (والتى قد تصيب أكثر من 1 لكل 10 أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى بفيروس الأنفلونزا مع أعراض مثل التعب والقشعريرة والتهاب الحلق وآلام في المفاصل أو العضلات مع وجود حمى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضغط أو الألم في الخدين والجبهة (التهاب الجيوب الأنفية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الرأس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات إنزيمات الكبد والتى تتضح من خلال اختبار الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">أعراض جانبية شائعة (والتى قد تصيب ما يصل إلى 1 لكل 10 أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السعفة، وهو التهاب فطري في الجلد (سعفة متعددة الألوان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع شديد غالباً ما يكون مصحوباً بغثيان وقيء وحساسية للضوء (صداع نصفي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى خلايا الدم البيضاء (الخلايا اللمفاوية، الكريات البيض)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مصحوب باحمرار وألم يشبه الحرق مع وجود حكة (إكزيما)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى الدهون الثلاثية بالدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقطاع النفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية (انظر أيضاً الفقرة الخاصة بالوذمة البقعية تحت عنوان &quot;بعض الأعراض الجانبية قد تكون أو قد تصبح خطيرة&quot;).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم (جوليمارا قد يسبب زيادة طفيفة في ضغط الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالعضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمفاصل.</p><p dir="RTL">أعراض جانبية غير شائعة (والتى قد تصيب ما يصل إلى 1 لكل 100 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى نوع معين من خلايا الدم البيضاء (النيوتروفيلات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب المزاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان.</p><p dir="RTL">أعراض جانبية نادرة (والتى قد تصيب ما يصل إلى 1 لكل 1000 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات فى الأوعية الدموية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات فى الجهاز العصبي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان فى الجهاز الليمفاوي (ورم ليمفاوي).</p><p dir="RTL">أعراض جانبية غير معروفة (لا يمكن تقدير معدل تكرارها من خلال البيانات المتاحة):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم فى الأطراف.</p><p dir="RTL">إذا تعرضت لتأثير أى مما سبق بشدة، أخبر طبيبك المعالج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيداً عن متناول ونظر الأطفال.</p><p dir="RTL">لا تستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على كل من العبوة والشريط بعد كلمة &ldquo;EXP&rdquo;. علماً بأن تاريخ الانتهاء يشير إلى آخر يوم فى الشهر المذكور.</p><p dir="RTL">لا يحفظ في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">لا تستعمل هذا الدواء إذا لاحظت أى تلف فى العبوة أو أى علامات تدل على العبث بها.</p><p dir="RTL">يجب عدم التخلص من الأدوية عبر مياه الصرف الصحى أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. سوف تعمل هذه التدابير على حماية البيئة. &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هى فينجوليمود.</p><p dir="RTL">تحتوي كل كبسولة صلبة على 0.5 ملجم من مادة فينجوليمود (على هيئة هيدروكلورايد).</p><p dir="RTL">مكونات أخرى وهي:</p><p dir="RTL">داخل كبسولة: ثلاثى كالسيوم فوسفات، حمض دهني 50</p><p dir="RTL">غلاف الكبسولة: جيلاتين، ثاني أكسيد تيتانيوم (E171) وأكسيد حديد أصفر(E172).</p><p dir="RTL">حبر الطباعة: شيلاك، أكسيد حديد أسود (E172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتوفر كبسولات جوليمارا 0.5 ملجم على هيئة مسحوق أبيض إلى أبيض فاتح داخل غطاء أصفر غامق وجسم أبيض داكن مقاس رقم 3 كبسولة جيلاتينية صلبة بطول 15.9 &plusmn; 0.3 مم، مطبوع عليها &quot;0.5 ملجم&quot; على الغطاء بحبر أسود.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم تغليف كبسولات جوليمارا 0.5 ملجم في صندوق من الورق المقوى يحتوي على العدد المناسب من شرائط رقائق الألمنيوم PVC / PE / PVDC بها عدد مناسب من الكبسولات ونشرة معلومات المريض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>أحجام العبوات:</u></p><p dir="RTL">العبوات تحتوي على 28 أو 98 كبسولة صلبة.</p><p>قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المصنع:</p><p dir="RTL"><strong>فارماثين أنترناشونال إس إيه</strong></p><p dir="RTL">سابس بارك الصناعية،</p><p dir="RTL">محافظة روبودي،</p><p dir="RTL">بلوك 5، رودوبي 69300</p><p dir="RTL">اليونان</p><p dir="RTL">&nbsp;</p><p dir="RTL">صاحب ترخيص التسويق والتغليف الثانوي:</p><p dir="RTL"><strong>سبيماكو</strong><strong> </strong></p><p dir="RTL">مصنع الأدوية بالقصيم</p><p dir="RTL">المملكة العربية السعودية</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أبريل 2022                                 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Golimara 0.5 mg hard capsules 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each hard capsule contains 0.5 mg fingolimod (as hydrochloride).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule 

White to off-white powder in a yellow opaque cap and white opaque body size No 3 hard gelatin capsule with length 15.9 ± 0.3 mm, imprinted with “0.5 mg” on the cap with black ink.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Golimara is indicated as single disease modifying therapy in highly active relapsing-remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>or</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Patients with rapidly evolving severe relapsing-remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The treatment should be initiated and supervised by a physician experienced in multiple sclerosis.</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p>In adults, the recommended dose of Golimara is one 0.5 mg hard capsule once daily.</p><p>&nbsp;</p><p>In paediatric patients (10 years of age and above), the recommended dose is dependent on body weight:</p><p>In paediatric patients with body weight &gt; 40 kg, the recommended dose of Golimara is one 0.5 mg hard capsule once daily.</p><p>&nbsp;</p><p>Other pharmaceutical strengths are more appropriate for administration to paediatric patients 10 years of age and above with body weight &le; 40 kg.</p><p>&nbsp;</p><p>The same first dose monitoring as for treatment initiation is recommended when treatment is interrupted for:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; 1 day or more during the first 2 weeks of treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; more than 7 days during weeks 3 and 4 of treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; more than 2 weeks after one month of treatment.</p><p><u>&nbsp;</u></p><p>If the treatment interruption is of shorter duration than the above, the treatment should be continued with the next dose as planned (see section 4.4).</p><p><u>&nbsp;</u></p><p><em><u>Special populations</u></em></p><p><u>&nbsp;</u></p><p><em>Elderly </em></p><p>Golimara should be used with caution in patients aged 65 years and over due to insufficient data on safety and efficacy (see section 5.2).</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>Fingolimod was not studied in patients with renal impairment in the multiple sclerosis pivotal studies.</p><p>Based on clinical pharmacology studies, no dose adjustments are needed in patients with mild to severe renal impairment.</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>Golimara must not be used in patients with severe hepatic impairment (Child-Pugh class C) (see section 4.3). Although no dose adjustments are needed in patients with mild or moderate hepatic impairment, caution should be exercised when initiating treatment in these patients (see sections 4.4 and 5.2).</p><p><em>&nbsp;</em></p><p><em>Diabetic patients</em></p><p>Fingolimod has not been studied in multiple sclerosis patients with concomitant diabetes mellitus.</p><p>Golimara should be used with caution in these patients due to a potential increase in the risk of macular oedema (see sections 4.4 and 4.8). Regular ophthalmological examinations should be conducted in these patients to detect macular oedema.</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>The safety and efficacy of fingolimod in children aged below 10 years have not yet been established. No data are available.</p><p>&nbsp;</p><p>There are very limited data available in children between 10&ndash;12 years old (see sections 4.4, 4.8 and 5.1).</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>For oral use.</p><p>Golimara can be taken with or without food.</p><p>The hard capsules should always be swallowed intact, without opening them.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
-	Known immunodeficiency syndrome.
-	Patients with increased risk for opportunistic infections, including immunocompromised patients (including those currently receiving immunosuppressive therapies or those immunocompromised by prior therapies).
-	Severe active infections, active chronic infections (hepatitis, tuberculosis).
-	Known active malignancies.
-	Severe liver impairment (Child-Pugh class C).
-	Patients who in the previous 6 months had myocardial infarction (MI), unstable angina pectoris, stroke/transient ischaemic attack (TIA), decompensated heart failure (requiring inpatient treatment) or New York Heart Association (NYHA) class III/IV heart failure (see section 4.4).
-	Patients with severe cardiac arrhythmias requiring anti-arrhythmic treatment with class Ia or class III anti-arrhythmic medicinal products (see section 4.4).
-	Patients with second-degree Mobitz type II atrioventricular (AV) block or third-degree AV block, or sick-sinus syndrome, if they do not wear a pacemaker (see section 4.4).
-	Patients with a baseline QTc interval ≥ 500 msec (see section 4.4).
-	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Bradyarrhythmia</u></p><p>Initiation of fingolimod treatment results in a transient decrease in heart rate and may also be associated with atrioventricular conduction delays, including the occurrence of isolated reports of transient, spontaneously resolving complete AV block (see sections 4.8 and 5.1).</p><p>&nbsp;</p><p>After the first dose, the decline in heart rate starts within one hour and is maximal within 6 hours.</p><p>This post-dose effect persists over the following days, although usually to a milder extent, and usually</p><p>abates over the next weeks. With continued administration, the average heart rate returns towards</p><p>baseline within one month. However, individual patients may not return to baseline heart rate by the</p><p>end of the first month. Conduction abnormalities were typically transient and asymptomatic. They</p><p>usually did not require treatment and resolved within the first 24 hours on treatment. If necessary, the</p><p>decrease in heart rate induced by fingolimod can be reversed by parenteral doses of atropine or</p><p>isoprenaline.</p><p>&nbsp;</p><p>All patients should have an ECG and blood pressure measurement performed prior to and 6 hours</p><p>after the first dose of Golimara. All patients should be monitored for a period of 6 hours for signs and symptoms of bradycardia with hourly heart rate and blood pressure measurement. Continuous (real time) ECG monitoring during this 6 hour period is recommended.</p><p>&nbsp;</p><p>Should post-dose bradyarrhythmia-related symptoms occur, appropriate clinical management should be initiated and monitoring should be continued until the symptoms have resolved. Should a patient require pharmacological intervention during the first-dose monitoring, overnight monitoring in a medical facility should be instituted and the first-dose monitoring should be repeated after the second</p><p>dose of Golimara.</p><p>&nbsp;</p><p>If the heart rate at 6 hours is the lowest since the first dose was administered (suggesting that the</p><p>maximum pharmacodynamic effect on the heart may not yet be manifest), monitoring should be</p><p>extended by at least 2 hours and until heart rate increases again. Additionally, if after 6 hours, the</p><p>heart rate is &lt; 45 bpm in adults, &lt; 55 bpm in paediatric patients aged 12 years and above or &lt; 60 bpm in paediatric patients aged 10 to below 12 years or the ECG shows new onset second degree or higher grade AV block or a QTc interval &ge; 500 msec, extended monitoring (at least overnight monitoring) should be performed and until the findings have resolved. The occurrence at any time of third degree AV block should also lead to extended monitoring (at least overnight monitoring).</p><p>&nbsp;</p><p>Very rare cases of T-wave inversion have been reported in adult patients treated with fingolimod. In case of T-wave inversion, the prescriber should ensure that there are no associated myocardial ischaemia signs or symptoms. If myocardial ischaemia is suspected, it is recommended to seek advice from a cardiologist.</p><p>&nbsp;</p><p>Due to the risk of serious rhythm disturbances or significant bradycardia, Golimara should not be used in patients with sino-atrial heart block, a history of symptomatic bradycardia, recurrent syncope or cardiac arrest or in patients with significant QT prolongation (QTc &gt; 470 msec [adult female], QTc &gt; 460 msec [paediatric female] or &gt; 450 msec [adult and paediatric male]), uncontrolled hypertension or severe sleep apnoea (see also section 4.3). In such patients, treatment with Golimara should be considered only if the anticipated benefits outweigh the potential risks and advice from a cardiologist sought prior to initiation of treatment in order to determine the most appropriate monitoring. At least overnight extended monitoring is recommended for treatment initiation (see also section 4.5).</p><p>&nbsp;</p><p>Fingolimod has not been studied in patients with arrhythmias requiring treatment with class Ia (e.g.</p><p>quinidine, disopyramide) or class III (e.g. amiodarone, sotalol) antiarrhythmic medicinal products.</p><p>Class Ia and class III antiarrhythmic medicinal products have been associated with cases of torsades</p><p>de pointes in patients with bradycardia (see section 4.3).</p><p>&nbsp;</p><p>Experience with fingolimod is limited in patients receiving concurrent therapy with beta blockers, heart rate-lowering calcium channel blockers (such as verapamil or diltiazem) or other substances which may decrease heart rate (e.g. ivabradine, digoxin, anticholinesteratic agents or pilocarpine). Since the initiation of fingolimod treatment is also associated with slowing of the heart rate (see also section 4.8 &ldquo;Bradyarrhythmia&rdquo;), concomitant use of these substances during fingolimod initiation may be associated with severe bradycardia and heart block. Because of the potential additive effect on heart rate, treatment with Golimara should not be initiated in patients who are concurrently treated with these substances (see also section 4.5). In such patients, treatment with Golimara should be considered only if the anticipated benefits outweigh the potential risks. If treatment with Golimara is considered, advice from a cardiologist should be sought regarding the switch to non-heart rate-lowering medicinal products prior to initiation of treatment. If the heart rate-lowering medicinal product cannot be stopped, cardiologist&rsquo;s advice should be sought to determine appropriate first dose monitoring, at least overnight extended monitoring is recommended (see also section 4.5).</p><p>&nbsp;</p><p>The effects on heart rate and atrioventricular conduction may recur on re-introduction of fingolimod</p><p>treatment depending on duration of the interruption and time since start of fingolimod treatment. The</p><p>same first dose monitoring as for treatment initiation is recommended when treatment is interrupted</p><p>for:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; 1 day or more during the first 2 weeks of treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; more than 7 days during weeks 3 and 4 of treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; more than 2 weeks after one month of treatment.</p><p>&nbsp;</p><p>If the treatment interruption is of shorter duration than the above, the treatment should be continued</p><p>with the next dose as planned.</p><p>&nbsp;</p><p><u>QT interval</u></p><p>In a thorough QT interval study of doses of 1.25 or 2.5 mg fingolimod at steady-state, when a negative</p><p>chronotropic effect of fingolimod was still present, fingolimod treatment resulted in a prolongation of</p><p>QTcI, with the upper limit of the 90 % CI &le; 13.0 ms. There is no dose- or exposure-response</p><p>relationship of fingolimod and QTcI prolongation. There is no consistent signal of increased</p><p>incidence of QTcI outliers, either absolute or change from baseline, associated with fingolimod</p><p>treatment.</p><p>&nbsp;</p><p>The clinical relevance of this finding is unknown. In the multiple sclerosis studies, clinically relevant</p><p>effects on prolongation of the QTc interval have not been observed but patients at risk for QT</p><p>prolongation were not included in clinical studies.</p><p>&nbsp;</p><p>Medicinal products that may prolong QTc interval are best avoided in patients with relevant risk</p><p>factors, for example, hypokalaemia or congenital QT prolongation.</p><p>&nbsp;</p><p><u>Immunosuppressive effects</u></p><p>Fingolimod has an immunosuppressive effect that predisposes patients to an infection risk, including</p><p>opportunistic infections that can be fatal, and increases the risk of developing lymphomas and other</p><p>malignancies, particularly those of the skin. Physicians should carefully monitor patients, especially</p><p>those with concurrent conditions or known factors, such as previous immunosuppressive therapy. If</p><p>this risk is suspected, discontinuation of treatment should be considered by the physician on a case by case basis (see also section 4.4 &ldquo;Infections&rdquo; and &ldquo;Cutaneous neoplasms&rdquo; and section 4.8 &ldquo;Lymphomas&rdquo;).</p><p>&nbsp;</p><p><u>Infections</u></p><p>A core pharmacodynamic effect of fingolimod is a dose-dependent reduction of the peripheral</p><p>lymphocyte count to 20-30 % of baseline values. This is due to the reversible sequestration of</p><p>lymphocytes in lymphoid tissues (see section 5.1).</p><p>&nbsp;</p><p>Before initiating treatment with Golimara, a recent complete blood count (CBC) (i.e. within 6 months or after discontinuation of prior therapy) should be available. Assessments of CBC are also</p><p>recommended periodically during treatment, at month 3 and at least yearly thereafter, and in case of</p><p>signs of infection. Absolute lymphocyte count &lt; 0.2 x 10<sup>9</sup>/L, if confirmed, should lead to treatment</p><p>interruption until recovery, because in clinical studies, fingolimod treatment was interrupted in</p><p>patients with absolute lymphocyte count &lt; 0.2 x 10<sup>9</sup>/L.</p><p>&nbsp;</p><p>Initiation of treatment with Golimara should be delayed in patients with severe active infection until resolution.</p><p>&nbsp;</p><p>Patients need to be assessed for their immunity to varicella (chickenpox) prior to Golimara treatment. It is recommended that patients without a healthcare professional confirmed history of chickenpox or documentation of a full course of vaccination with varicella vaccine undergo antibody testing to varicella zoster virus (VZV) before initiating Golimara therapy. A full course of vaccination for antibody-negative patients with varicella vaccine is recommended prior to commencing treatment with Golimara (see section 4.8). Initiation of treatment with Golimara should be postponed for 1 month to allow full effect of vaccination to occur.</p><p>&nbsp;</p><p>The immune system effects of fingolimod may increase the risk of infections, including opportunistic</p><p>infections (see section 4.8). Effective diagnostic and therapeutic strategies should be employed in</p><p>patients with symptoms of infection while on therapy. When evaluating a patient with a suspected</p><p>infection that could be serious, referral to a physician experienced in treating infections should be</p><p>considered. During treatment, patients receiving Golimara should be instructed to report promptly symptoms of infection to their physician.</p><p>&nbsp;</p><p>Suspension of Golimara should be considered if a patient develops a serious infection and</p><p>consideration of benefit-risk should be undertaken prior to re-initiation of therapy.</p><p>&nbsp;</p><p>Cases of cryptococcal meningitis (a fungal infection), sometimes fatal, have been reported in the post-marketing setting after approximately 2-3 years of treatment, although an exact relationship with the</p><p>duration of treatment is unknown (see section 4.8). Patients with symptoms and signs consistent with</p><p>cryptococcal meningitis (e.g. headache accompanied by mental changes such as confusion,</p><p>hallucinations and/or personality changes) should undergo prompt diagnostic evaluation. If</p><p>cryptococcal meningitis is diagnosed, fingolimod should be suspended and appropriate treatment</p><p>should be initiated. A multidisciplinary consultation (i.e. infectious disease specialist) should be</p><p>undertaken if re-initiation of fingolimod is warranted.</p><p>&nbsp;</p><p>Progressive multifocal leukoencephalopathy (PML) has been reported under fingolimod treatment</p><p>since marketing AUTHORIZATION (see section 4.8). PML is an opportunistic infection caused by John</p><p>Cunningham virus (JCV), which may be fatal or result in severe disability. Cases of PML have</p><p>occurred after approximately 2-3 years of monotherapy treatment without previous exposure to</p><p>natalizumab, although an exact relationship with the duration of treatment is unknown. Additional</p><p>PML cases have occurred in patients who had been treated previously with natalizumab, which has a</p><p>known association with PML. PML can only occur in the presence of a JCV infection. If JCV testing</p><p>is undertaken, it should be considered that the influence of lymphopenia on the accuracy of anti-JCV</p><p>antibody testing has not been studied in fingolimod-treated patients. It should also be noted that a</p><p>negative anti-JCV antibody test does not preclude the possibility of subsequent JCV infection. Before</p><p>initiating treatment with fingolimod, a baseline MRI should be available (usually within 3 months) as</p><p>a reference. During routine MRI (in accordance with national and local recommendations), physicians</p><p>should pay attention to PML suggestive lesions. MRI may be considered as part of increased vigilance</p><p>in patients considered at increased risk of PML. If PML is suspected, MRI should be performed</p><p>immediately for diagnostic purposes and treatment with fingolimod should be suspended until PML</p><p>has been excluded.</p><p>&nbsp;</p><p>Human papilloma virus (HPV) infection, including papilloma, dysplasia, warts and HPV-related cancer, has been reported under treatment with fingolimod in the post-marketing setting. Due to the immunosuppressive properties of fingolimod, vaccination against HPV should be considered prior to treatment initiation with fingolimod taking into account vaccination recommendations. Cancer screening, including Pap test, is recommended as per standard of care.</p><p>&nbsp;</p><p>Elimination of fingolimod following discontinuation of therapy may take up to two months and</p><p>vigilance for infection should therefore be continued throughout this period. Patients should be</p><p>instructed to report symptoms of infection up to 2 months after discontinuation of fingolimod.</p><p><u>&nbsp;</u></p><p><u>Macular oedema</u></p><p>Macular oedema with or without visual symptoms has been reported in 0.5 % of patients treated with</p><p>fingolimod 0.5 mg, occurring predominantly in the first 3-4 months of therapy (see section 4.8). An</p><p>ophthalmological evaluation is therefore recommended at 3-4 months after treatment initiation. If</p><p>patients report visual disturbances at any time while on therapy, evaluation of the fundus, including</p><p>the macula, should be carried out.</p><p>&nbsp;</p><p>Patients with history of uveitis and patients with diabetes mellitus are at increased risk of macular</p><p>oedema (see section 4.8). Fingolimod has not been studied in multiple sclerosis patients with concomitant diabetes mellitus. It is recommended that multiple sclerosis patients with diabetes mellitus or a history of uveitis undergo an ophthalmological evaluation prior to initiating therapy and have follow-up evaluations while receiving therapy.</p><p>&nbsp;</p><p>Continuation of fingolimod in patients with macular oedema has not been evaluated. It is recommended that Golimara be discontinued if a patient develops macular oedema. A decision on whether or not Golimara therapy should be re-initiated after resolution of macular oedema needs to take into account the potential benefits and risks for the individual patient.</p><p><u>&nbsp;</u></p><p><u>Liver function</u></p><p>Increased hepatic enzymes, in particular alanine aminotransaminase (ALT) but also gamma</p><p>glutamyltransferase (GGT) and aspartate transaminase (AST) have been reported in multiple sclerosis</p><p>patients treated with fingolimod. In clinical trials, elevations 3-fold the upper limit of normal (ULN) or greater in ALT occurred in 8.0 % of adult patients treated with fingolimod 0.5 mg compared to 1.9 % of placebo patients. Elevations 5-fold the ULN occurred in 1.8 % of patients on fingolimod and 0.9 % of patients on placebo. In clinical trials, fingolimod was discontinued if the elevation exceeded 5 times the ULN. Recurrence of liver transaminase elevations occurred with rechallenge in some patients, supporting a relationship to fingolimod. In clinical studies, transaminase elevations occurred at any time during treatment although the majority occurred within the first 12 months. Serum transaminase levels returned to normal within approximately 2 months after discontinuation of fingolimod.</p><p>&nbsp;</p><p>Fingolimod has not been studied in patients with severe pre-existing hepatic injury (Child-Pugh class C) and should not be used in these patients (see section 4.3).</p><p>&nbsp;</p><p>Due to the immunosuppressive properties of fingolimod, initiation of treatment should be delayed in</p><p>patients with active viral hepatitis until resolution.</p><p>&nbsp;</p><p>Recent (i.e. within last 6 months) transaminase and bilirubin levels should be available before</p><p>initiation of treatment with Golimara. In the absence of clinical symptoms, liver transaminases should be monitored at months 1, 3, 6, 9 and 12 on therapy and periodically thereafter. If liver transaminases rise above 5 times the ULN, more frequent monitoring should be instituted, including serum bilirubin and alkaline phosphatase (ALP) measurement. With repeated confirmation of liver transaminases above 5 times the ULN, treatment with Golimara should be interrupted and only re-commenced once liver transaminase values have normalised.</p><p>&nbsp;</p><p>Patients who develop symptoms suggestive of hepatic dysfunction, such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia or jaundice and/or dark urine, should have liver enzymes</p><p>checked and Golimara should be discontinued if significant liver injury is confirmed (for example, liver transaminase levels greater than 5-fold the ULN and/or serum bilirubin elevations). Resumption of therapy will be dependent on whether or not another cause of liver injury is determined and on the benefits to patient of resuming therapy versus the risks of recurrence of liver dysfunction.</p><p>&nbsp;</p><p>Although there are no data to establish that patients with pre-existing liver disease are at increased risk of developing elevated liver function tests when taking fingolimod, caution in the use of Golimara should be exercised in patients with a history of significant liver disease.</p><p><u>&nbsp;</u></p><p><u>Interference with serological testing</u></p><p>Since fingolimod reduces blood lymphocyte counts via re-distribution in secondary lymphoid organs,</p><p>peripheral blood lymphocyte counts cannot be utilised to evaluate the lymphocyte subset status of a</p><p>patient treated with fingolimod. Laboratory tests involving the use of circulating mononuclear cells</p><p>require larger blood volumes due to reduction in the number of circulating lymphocytes.</p><p><u>&nbsp;</u></p><p><u>Blood pressure effects</u></p><p>Patients with hypertension uncontrolled by medicinal product were excluded from participation in pre-marketing clinical trials and special care is indicated if patients with uncontrolled hypertension are treated with Golimara.</p><p>&nbsp;</p><p>In MS clinical trials, patients treated with fingolimod 0.5 mg had an average increase of</p><p>approximately 3 mmHg in systolic pressure and approximately 1 mmHg in diastolic pressure, first</p><p>detected approximately 1 month after treatment initiation and persisting with continued treatment. In</p><p>the two-year placebo-controlled study, hypertension was reported as an adverse event in 6.5 % of</p><p>patients on fingolimod 0.5 mg and in 3.3 % of patients on placebo. Therefore, blood pressure should</p><p>be regularly monitored during treatment with Golimara.</p><p><u>&nbsp;</u></p><p><u>Respiratory effects</u></p><p>Minor dose-dependent reductions in values for forced expiratory volume (FEV<sub>1</sub>) and diffusion</p><p>capacity for carbon monoxide (DLCO) were observed with fingolimod treatment starting at month 1 and remaining stable thereafter. Golimara should be used with caution in patients with severe respiratory disease, pulmonary fibrosis and chronic obstructive pulmonary disease (see also section 4.8).</p><p>&nbsp;</p><p><u>Posterior reversible encephalopathy syndrome</u></p><p>Rare cases of posterior reversible encephalopathy syndrome (PRES) have been reported at the 0.5 mg</p><p>dose in clinical trials and in the post-marketing setting (see section 4.8). Symptoms reported included</p><p>sudden onset of severe headache, nausea, vomiting, altered mental status, visual disturbances and</p><p>seizure. Symptoms of PRES are usually reversible but may evolve into ischaemic stroke or cerebral</p><p>haemorrhage. Delay in diagnosis and treatment may lead to permanent neurological sequelae. If PRES</p><p>is suspected, Golimara should be discontinued.</p><p><u>&nbsp;</u></p><p><u>Prior treatment with immunosuppressive or immunomodulatory therapies</u></p><p>There have been no studies performed to evaluate the efficacy and safety of fingolimod when switching patients from teriflunomide, dimethyl fumarate or alemtuzumab treatment to fingolimod. When switching patients from another disease modifying therapy to Golimara, the half-life and mode of action of the other therapy must be considered in order to avoid an additive immune effect whilst at the same time minimising the risk of disease reactivation. A CBC is recommended prior to initiating Golimara to ensure that immune effects of the previous therapy (i.e. cytopenia) have resolved.</p><p>&nbsp;</p><p>Golimara can generally be started immediately after discontinuation of interferon or glatiramer acetate.</p><p>&nbsp;</p><p>For dimethyl fumarate, the washout period should be sufficient for CBC to recover before treatment</p><p>with Golimara is started.</p><p>&nbsp;</p><p>Due to the long half-life of natalizumab, elimination usually takes up to 2-3 months following</p><p>discontinuation. Teriflunomide is also eliminated slowly from the plasma. Without an accelerated</p><p>elimination procedure, clearance of teriflunomide from plasma can take from several months up to</p><p>2 years. An accelerated elimination procedure as defined in the teriflunomide summary of product</p><p>characteristics is recommended or alternatively washout period should not be shorter than 3.5 months.</p><p>Caution regarding potential concomitant immune effects is required when switching patients from</p><p>natalizumab or teriflunomide to Golimara.</p><p>&nbsp;</p><p>Alemtuzumab has profound and prolonged immunosuppressive effects. As the actual duration of these</p><p>effects is unknown, initiating treatment with Golimara after alemtuzumab is not recommended unless the benefits of such treatment clearly outweigh the risks for the individual patient.</p><p>&nbsp;</p><p>A decision to use prolonged concomitant treatment with corticosteroids should be taken after careful</p><p>consideration.</p><p><u>&nbsp;</u></p><p><u>Co-administration with potent CYP450 inducers</u></p><p>The combination of fingolimod with potent CYP450 inducers should be used with caution. Concomitant administration with St John&rsquo;s Wort is not recommended (see section 4.5).</p><p><u>&nbsp;</u></p><p><u>Cutaneous neoplasms</u></p><p>Basal cell carcinoma (BCC) and other cutaneous neoplasms, including malignant melanoma,</p><p>squamous cell carcinoma, Kaposi&rsquo;s sarcoma and Merkel cell carcinoma, have been reported in</p><p>patients receiving fingolimod (see section 4.8). Vigilance for skin lesions is warranted and a medical</p><p>evaluation of the skin is recommended at initiation and then every 6 to 12 months taking into</p><p>consideration clinical judgement. The patient should be referred to a dermatologist in case suspicious</p><p>lesions are detected.</p><p>&nbsp;</p><p>Since there is a potential risk of malignant skin growths, patients treated with fingolimod should be</p><p>cautioned against exposure to sunlight without protection. These patients should not receive</p><p>concomitant phototherapy with UVB-radiation or PUVA-photochemotherapy.</p><p><u>&nbsp;</u></p><p><u>Return of disease activity (rebound)</u></p><p>In the post-marketing setting, severe exacerbation of disease has been observed rarely in some</p><p>patients stopping fingolimod. The possibility of recurrence of exceptionally high disease activity</p><p>should be considered (see &ldquo;Stopping therapy&rdquo; below).</p><p><u>&nbsp;</u></p><p><u>Stopping therapy</u></p><p>If a decision is made to stop treatment with Golimara, a 6-week interval without therapy is needed, based on half-life, to clear fingolimod from the circulation (see section 5.2). Lymphocyte counts progressively return to normal range within 1-2 months of stopping therapy in most patients (see section 5.1), although full recovery can take significantly longer in some patients. Starting other</p><p>therapies during this interval will result in concomitant exposure to fingolimod. Use of immunosuppressants soon after the discontinuation of fingolimod may lead to an additive effect on the immune system and caution is therefore indicated.</p><p>&nbsp;</p><p>Caution is also indicated when stopping fingolimod therapy due to the risk of a rebound (see &ldquo;Return</p><p>of disease activity (rebound)&rdquo; above). If discontinuation of Golimara is deemed necessary, patients should be monitored during this time for relevant signs of a possible rebound.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety profile in paediatric patients is similar to that in adults and the warnings and precautions for adults, therefore, also apply to paediatric patients.</p><p>&nbsp;</p><p>In particular, the following should be noted when prescribing Golimara to paediatric patients:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Precautions should be followed at the time of the first dose (see &ldquo;Bradyarrhythmia&rdquo; above).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; In the controlled paediatric trial D2311, cases of seizures, anxiety, depressed mood and depression have been reported with a higher incidence in patients treated with fingolimod compared to patients treated with interferon beta-1a. Caution is required in this subgroup population (see &ldquo;Paediatric population&rdquo; in section 4.8).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Mild isolated bilirubin increases have been noted in paediatric patients on fingolimod.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; It is recommended that paediatric patients complete all immunisations in accordance with current immunisation guidelines before starting Golimara therapy (see &ldquo;Infections&rdquo; above).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; There are very limited data available in children between 10&ndash;12 years old, less than 40 kg or at Tanner stage &lt; 2 (see sections 4.8 and 5.1). Caution is required in these subgroups due to very limited knowledge available from the clinical study.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Long-term safety data in the paediatric population are not available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Anti-neoplastic, immunomodulatory or immunosuppressive therapies</u></p><p>Anti-neoplastic, immunomodulatory or immunosuppressive therapies should not be co-administered due to the risk of additive immune system effects (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p>Caution should also be exercised when switching patients from long-acting therapies with immune effects such as natalizumab, teriflunomide or mitoxantrone (see section 4.4). In multiple sclerosis clinical studies the concomitant treatment of relapses with a short course of corticosteroids was not associated with an increased rate of infection.</p><p>&nbsp;</p><p><u>Vaccination</u></p><p>During and for up to two months after treatment with fingolimod vaccination may be less effective. The use of live attenuated vaccines may carry a risk of infections and should therefore be avoided (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p><u>Bradycardia-inducing substances</u></p><p>Fingolimod has been studied in combination with atenolol and diltiazem. When fingolimod was used with atenolol in an interaction study in healthy volunteers, there was an additional 15 % reduction of heart rate at fingolimod treatment initiation, an effect not seen with diltiazem. Treatment with fingolimod should not be initiated in patients receiving beta blockers, or other substances which may decrease heart rate, such as class Ia and III antiarrhythmics, calcium channel blockers (such as verapamil or diltiazem), ivabradine, digoxin, anticholinesteratic agents or pilocarpine because of the potential additive effects on heart rate (see sections 4.4 and 4.8). If treatment with fingolimod is considered in such patients, advice from a cardiologist should be sought regarding the switch to non-heart rate-lowering medicinal products or appropriate monitoring for treatment initiation, at least overnight monitoring, is recommended, if the heart rate-lowering medicinal product cannot be stopped.</p><p>&nbsp;</p><p><u>Pharmacokinetic interactions of other substances on fingolimod</u></p><p>Fingolimod is metabolised mainly by CYP4F2. Other enzymes like CYP3A4 may also contribute to its metabolism, notably in the case of strong induction of CYP3A4. Potent inhibitors of transporter proteins are not expected to influence fingolimod disposition. Co-administration of fingolimod with ketoconazole resulted in a 1.7-fold increase in fingolimod and fingolimod phosphate exposure (AUC) by inhibition of CYP4F2. Caution should be exercised with substances that may inhibit CYP3A4 (protease inhibitors, azole antifungals, some macrolides such as clarithromycin or telithromycin).</p><p>&nbsp;</p><p>Co-administration of carbamazepine 600 mg twice daily at steady-state and a single dose of fingolimod 2 mg reduced the AUC of fingolimod and its metabolite by approximately 40 %. Other strong CYP3A4 enzyme inducers, for example rifampicin, phenobarbital, phenytoin, efavirenz and St.</p><p>John&rsquo;s Wort, may reduce the AUC of fingolimod and its metabolite at least to this extent. As this could potentially impair the efficacy, their co-administration should be used with caution. Concomitant administration with St. John&rsquo;s Wort is, however, not recommended (see section 4.4).</p><p>&nbsp;</p><p><u>Pharmacokinetic interactions of fingolimod on other substances</u></p><p>Fingolimod is unlikely to interact with substances mainly cleared by the CYP450 enzymes or by substrates of the main transporter proteins.</p><p>&nbsp;</p><p>Co-administration of fingolimod with ciclosporin did not elicit any change in the ciclosporin or fingolimod exposure. Therefore, fingolimod is not expected to alter the pharmacokinetics of medicinal products that are CYP3A4 substrates.</p><p>&nbsp;</p><p>Co-administration of fingolimod with oral contraceptives (ethinylestradiol and levonorgestrel) did not elicit any change in oral contraceptive exposure. No interaction studies have been performed with oral contraceptives containing other progestagens, however, an effect of fingolimod on their exposure is not expected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential / Contraception in females</u></p><p>Before initiation of treatment in women of childbearing potential, a negative pregnancy test result needs to be available and counselling should be provided regarding the potential for serious risk to the foetus and the need for effective contraception during treatment with Golimara. Since it takes approximately two months to eliminate fingolimod from the body on stopping treatment (see section 4.4), the potential risk to the foetus may persist and contraception should be continued during that period.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>While on treatment, women should not become pregnant and active contraception is recommended. If a woman becomes pregnant while taking Golimara, discontinuation of Golimara is recommended.</p><p>&nbsp;</p><p>Animal studies have shown reproductive toxicity including foetal loss and organ defects, notably persistent truncus arteriosus and ventricular septal defect (see section 5.3). Furthermore, the receptor affected by fingolimod (sphingosine 1-phosphate receptor) is known to be involved in vascular formation during embryogenesis. There are very limited data from the use of fingolimod in pregnant women.</p><p>&nbsp;</p><p>There are no data on the effects of fingolimod on labour and delivery.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Fingolimod is excreted in milk of treated animals during lactation (see section 5.3). Due to the potential for serious adverse reactions to fingolimod in nursing infants, women receiving Golimara should not breast-feed.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Data from preclinical studies do not suggest that fingolimod would be associated with an increased risk of reduced fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Golimara has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>However, dizziness or drowsiness may occasionally occur when initiating therapy with Golimara. On initiation of Golimara treatment it is recommended that patients be observed for a period of 6 hours (see section 4.4 &ldquo;Bradyarrhythmia&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety population of fingolimod is derived from two Phase III placebo-controlled clinical studies and one Phase III active-controlled clinical study in adult patients with relapsing-remitting multiple sclerosis. It includes a total of 2,431 adult patients on fingolimod (0.5 or 1.25 mg). Study D2301 (FREEDOMS) was a 2-year placebo-controlled clinical study in 854 adult patients treated with fingolimod (placebo: 418). Study D2309 (FREEDOMS II) was a 2-year placebo-controlled clinical study in 728 multiple sclerosis adult patients treated with fingolimod (placebo: 355). In the pooled data from these two studies the most serious adverse reactions on fingolimod 0.5 mg were infections, macular oedema and transient atrioventricular block at treatment initiation. The most frequent adverse reactions (incidence &ge; 10 %) on fingolimod 0.5 mg were influenza, sinusitis, headache, diarrhoea, back pain, hepatic enzyme increased and cough. The most frequent adverse reaction reported for fingolimod 0.5 mg leading to treatment interruption was ALT elevations (2.2 %). The adverse reactions in Study D2302 (TRANSFORMS), a 1-year study in 849 adult patients treated with fingolimod which used interferon beta-1a as comparator, were generally similar to placebo-controlled studies, taking into account the differences in study duration.</p><p>&nbsp;</p><p>Adverse reactions reported with fingolimod 0.5 mg in Studies D2301 (FREEDOMS) and D2309</p><p>(FREEDOMS II) are shown below. Frequencies were defined using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to</p><p>&lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Influenza</p><p>Sinusitis</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Herpes viral infections</p><p>Bronchitis</p><p>Tinea versicolor</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Progressive multifocal leukoencephalopathy (PML)**</p><p>Cryptococcal infections**</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Basal cell carcinoma</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Malignant melanoma****</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Lymphoma***</p><p>Squamous cell carcinoma****</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Kaposi&rsquo;s sarcoma****</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Merkel cell carcinoma***</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Lymphopenia</p><p>Leucopenia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Peripheral oedema***</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions, including rash, urticaria and angioedema upon treatment initiation***</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Depression</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Depressed mood</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness</p><p>Migraine</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Seizure</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Posterior reversible encephalopathy syndrome (PRES)*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vision blurred</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Macular oedema</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Bradycardia</p><p>Atrioventricular block</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>T-wave inversion***</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypertension</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Nausea***</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Eczema</p><p>Alopecia</p><p>Pruritus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Back pain</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Myalgia</p><p>Arthralgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Asthenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations </strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hepatic enzyme increased (increased ALT, Gamma glutamyltransferase, Aspartate transaminase)</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Blood triglycerides increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Neutrophil count decreased</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not reported in Studies FREEDOMS, FREEDOMS II and TRANSFORMS. The frequency category was based on an estimated exposure of approximately 10,000 patients to fingolimod in all clinical trials.</p><p>** &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PML and cryptococcal infections (including cases of cryptococcal meningitis) have been reported in the post-marketing setting (see section 4.4).</p><p>*** &nbsp;&nbsp; Adverse drug reactions from spontaneous reports and literature.</p><p>**** The frequency category and risk assessment were based on an estimated exposure of more than 24,000 patients to fingolimod 0.5 mg in all clinical trials.</p><p><u>&nbsp;</u></p><p><u>Description of selected adverse reactions</u></p><p><em><u>&nbsp;</u></em></p><p><em><u>Infections</u></em></p><p>In multiple sclerosis clinical studies the overall rate of infections (65.1 %) at the 0.5 mg dose was similar to placebo. However, lower respiratory tract infections, primarily bronchitis and to a lesser extent herpes infection and pneumonia were more common in fingolimod-treated patients.</p><p>&nbsp;</p><p>Some cases of disseminated herpes infection, including fatal cases, have been reported even at the 0.5 mg dose.</p><p>&nbsp;</p><p>In the post-marketing setting, cases of infections with opportunistic pathogens, such as viral (e.g. varicella zoster virus [VZV], John Cunningham virus [JCV] causing Progressive Multifocal</p><p>Leukoencephalopathy, herpes simplex virus [HSV]) and fungal (e.g. cryptococci including cryptococcal meningitis) or bacterial (e.g. atypical mycobacterium), have been reported, some of which have been fatal (see section 4.4).</p><p><u>&nbsp;</u></p><p>Human papilloma virus (HPV) infection, including papilloma, dysplasia, warts and HPV-related cancer, has been reported under treatment with fingolimod in the post-marketing setting. Due to the immunosuppressive properties of fingolimod, vaccination against HPV should be considered prior to treatment initiation with fingolimod taking into account vaccination recommendations. Cancer screening, including Pap test, is recommended as per standard of care.</p><p><u>&nbsp;</u></p><p><em><u>Macular oedema</u></em></p><p>In multiple sclerosis clinical studies macular oedema occurred in 0.5 % of patients treated with the recommended dose of 0.5 mg and 1.1 % of patients treated with the higher dose of 1.25 mg. The majority of cases occurred within the first 3-4 months of therapy. Some patients presented with blurred vision or decreased visual acuity, but others were asymptomatic and diagnosed on routine ophthalmological examination. The macular oedema generally improved or resolved spontaneously after discontinuation of fingolimod. The risk of recurrence after re-challenge has not been evaluated.</p><p>&nbsp;</p><p>Macular oedema incidence is increased in multiple sclerosis patients with a history of uveitis (17 % with a history of uveitis vs. 0.6 % without a history of uveitis). Fingolimod has not been studied in multiple sclerosis patients with diabetes mellitus, a disease which is associated with an increased risk for macular oedema (see section 4.4). In renal transplant clinical studies in which patients with diabetes mellitus were included, therapy with fingolimod 2.5 mg and 5 mg resulted in a 2-fold increase in the incidence of macular oedema.</p><p><u>&nbsp;</u></p><p><em><u>Bradyarrhythmia</u></em></p><p>Initiation of fingolimod treatment results in a transient decrease in heart rate and may also be associated with atrioventricular conduction delays. In multiple sclerosis clinical studies the maximal decline in heart rate was seen within 6 hours after treatment initiation, with declines in mean heart rate of 12-13 beats per minute for fingolimod 0.5 mg. Heart rate below 40 beats per minute in adults, and below 50 beats per minute in paediatric patients, was rarely observed in patients on fingolimod 0.5 mg. The average heart rate returned towards baseline within 1 month of chronic treatment. Bradycardia was generally asymptomatic but some patients experienced mild to moderate symptoms, including hypotension, dizziness, fatigue and/or palpitations, which resolved within the first 24 hours after treatment initiation (see also sections 4.4 and 5.1).</p><p>&nbsp;</p><p>In multiple sclerosis clinical studies first-degree atrioventricular block (prolonged PR interval on</p><p>ECG) was detected after treatment initiation in adult and paediatric patients. In adult clinical trials it occurred in 4.7 % of patients on fingolimod 0.5 mg, in 2.8 % of patients on intramuscular interferon beta-1a and in 1.6 % of patients on placebo. Second-degree atrioventricular block was detected in less than 0.2 % adult patients on fingolimod 0.5 mg. In the post-marketing setting, isolated reports of transient, spontaneously resolving complete AV block have been observed during the six-hour monitoring period following the first dose of fingolimod. The patients recovered spontaneously. The conduction abnormalities observed both in clinical trials and post-marketing were typically transient, asymptomatic and resolved within the first 24 hours after treatment initiation. Although most patients did not require medical intervention, one patient on fingolimod 0.5 mg received isoprenaline for asymptomatic second-degree Mobitz I atrioventricular block.</p><p>&nbsp;</p><p>In the post-marketing setting, isolated delayed onset events, including transient asystole and unexplained death, have occurred within 24 hours of the first dose. These cases have been confounded by concomitant medicinal products and/or pre-existing disease. The relationship of such events to fingolimod is uncertain.</p><p><u>&nbsp;</u></p><p><em><u>Blood pressure</u></em></p><p>In multiple sclerosis clinical studies fingolimod 0.5 mg was associated with an average increase of approximately 3 mmHg in systolic pressure and approximately 1 mmHg in diastolic pressure, manifesting approximately 1 month after treatment initiation. This increase persisted with continued treatment. Hypertension was reported in 6.5 % of patients on fingolimod 0.5 mg and in 3.3 % of patients on placebo. In the post-marketing setting, cases of hypertension have been reported within the first month of treatment initiation and on the first day of treatment that may require treatment with anti-hypertensive agents or discontinuation of fingolimod (see also section 4.4 &ldquo;Blood pressure effects&rdquo;).</p><p><u>&nbsp;</u></p><p><em><u>Liver function</u></em></p><p>Increased hepatic enzymes have been reported in adult and paediatric multiple sclerosis patients treated with fingolimod. In clinical studies 8.0 % and 1.8 % of adult patients treated with fingolimod 0.5 mg experienced an asymptomatic elevation in serum levels of ALT of &ge; 3 x ULN (upper limit of normal) and &ge; 5 x ULN, respectively. Recurrence of liver transaminase elevations has occurred upon re-challenge in some patients, supporting a relationship to the medicinal product. In clinical studies, transaminase elevations occurred at any time during treatment although the majority occurred within the first 12 months. ALT levels returned to normal within approximately 2 months after discontinuation of fingolimod. In a small number of patients (n=10 on 1.25 mg, n=2 on 0.5 mg) who experienced ALT elevations &ge; 5 x ULN and who continued on fingolimod therapy, the ALT levels returned to normal within approximately 5 months (see also section 4.4 &ldquo;Liver function&rdquo;).</p><p>&nbsp;</p><p><em><u>Nervous system disorders</u></em></p><p>In clinical studies, rare events involving the nervous system occurred in patients treated with fingolimod at higher doses (1.25 or 5.0 mg), including ischaemic and haemorrhagic strokes and neurological atypical disorders, such as acute disseminated encephalomyelitis (ADEM)-like events.</p><p>&nbsp;</p><p>Cases of seizures, including status epilepticus, have been reported with the use of fingolimod in clinical studies and in the post-marketing setting.</p><p>&nbsp;</p><p><em><u>Vascular disorders</u></em></p><p>Rare cases of peripheral arterial occlusive disease occurred in patients treated with fingolimod at higher doses (1.25 mg).</p><p><u>&nbsp;</u></p><p><em><u>Respiratory system</u></em></p><p>Minor dose-dependent reductions in values for forced expiratory volume (FEV<sub>1</sub>) and diffusion capacity for carbon monoxide (DLCO) were observed with fingolimod treatment starting at month 1 and remaining stable thereafter. At month 24, the reduction from baseline values in percentage of predicted FEV<sub>1</sub> was 2.7 % for fingolimod 0.5 mg and 1.2 % for placebo, a difference that resolved after treatment discontinuation. For DLCO the reductions at month 24 were 3.3 % for fingolimod 0.5 mg and 2.7 % for placebo.</p><p><u>&nbsp;</u></p><p><em><u>Lymphomas</u></em></p><p>There have been cases of lymphoma of different varieties, in both clinical studies and the post-marketing setting, including a fatal case of Epstein-Barr virus (EBV) positive B-cell lymphoma. The incidence of lymphoma (B-cell and T-cell) cases was higher in clinical trials than expected in the general population. Some T-cell lymphoma cases were also reported in the post-marketing setting, including cases of cutaneous T-cell lymphoma (mycosis fungoides).</p><p><u>&nbsp;</u></p><p><em><u>Haemophagocytic syndrome</u></em></p><p>Very rare cases of haemophagocytic syndrome (HPS) with fatal outcome have been reported in patients treated with fingolimod in the context of an infection. HPS is a rare condition that has been described in association with infections, immunosuppression and a variety of autoimmune diseases.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>In the controlled paediatric trial D2311 (see section 5.1) the safety profile in paediatric patients (10 to below 18 years of age) receiving fingolimod 0.25 mg or 0.5 mg daily was overall similar to that seen in adult patients. There were, nevertheless, more neurological and psychiatric disorders observed in the study. Caution is needed in this subgroup due to very limited knowledge available from the clinical study.</p><p>&nbsp;</p><p>In the paediatric study, cases of seizures were reported in 5.6 % of fingolimod-treated patients and 0.9 % of interferon beta-1a-treated patients.</p><p>&nbsp;</p><p>Depression and anxiety are known to occur with increased frequency in the multiple sclerosis population. Depression and anxiety have also been reported in paediatric patients treated with fingolimod.</p><p>&nbsp;</p><p>Mild isolated bilirubin increases have been noted in paediatric patients on fingolimod.</p><p><u>&nbsp;</u></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>To report any side effect(s):</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Hotline: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses up to 80 times the recommended dose (0.5 mg) were well tolerated in healthy adult volunteers. At 40 mg, 5 of 6 subjects reported mild chest tightness or discomfort which was clinically consistent with small airway reactivity.</p><p>&nbsp;</p><p>Fingolimod can induce bradycardia upon treatment initiation. The decline in heart rate usually starts</p><p>within one hour of the first dose and is steepest within 6 hours. The negative chronotropic effect of</p><p>fingolimod persists beyond 6 hours and progressively attenuates over subsequent days of treatment (see section 4.4 for details). There have been reports of slow atrioventricular conduction, with isolated</p><p>reports of transient, spontaneously resolving complete AV block (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p>If the overdose constitutes first exposure to fingolimod, it is important to monitor patients with a</p><p>continuous (real time) ECG and hourly measurement of heart rate and blood pressure, at least during</p><p>the first 6 hours (see section 4.4).</p><p>&nbsp;</p><p>Additionally, if after 6 hours the heart rate is &lt; 45 bpm in adults, &lt; 55 bpm in paediatric patients aged 12 years and above or &lt; 60 bpm in paediatric patients aged 10 years to below 12 years or if the ECG at 6 hours after the first dose shows second degree or higher AV block or if it shows a QTc interval &ge; 500 msec, monitoring should be extended at least for overnight and until the findings have resolved. The occurrence at any time of third degree AV block should also lead to extended monitoring including overnight monitoring.</p><p>&nbsp;</p><p>Neither dialysis nor plasma exchange results in removal of fingolimod from the body.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Selective immunosuppressants, ATC code: L04AA27</p><p><em>&nbsp;</em></p><p><u>Mechanism of action</u></p><p>Fingolimod is a sphingosine 1-phosphate receptor modulator. Fingolimod is metabolised by sphingosine kinase to the active metabolite fingolimod phosphate. Fingolimod phosphate binds at low nanomolar concentrations to sphingosine 1-phosphate (S1P) receptor 1 located on lymphocytes and readily crosses the blood-brain barrier to bind to S1P receptor 1 located on neural cells in the central nervous system (CNS). By acting as a functional antagonist of S1P receptors on lymphocytes, fingolimod phosphate blocks the capacity of lymphocytes to egress from lymph nodes, causing a re-distribution, rather than depletion, of lymphocytes. Animal studies have shown that this re-distribution reduces the infiltration of pathogenic lymphocytes, including pro-inflammatory Th17 cells, into the CNS, where they would be involved in nerve inflammation and nervous tissue damage.</p><p>Animal studies and <em>in vitro</em> experiments indicate that fingolimod may also act via interaction with S1P receptors on neural cells.</p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects</u></p><p>Within 4-6 hours after the first dose of fingolimod 0.5 mg, the lymphocyte count decreases to approximately 75 % of baseline in peripheral blood. With continued daily dosing, the lymphocyte count continues to decrease over a two-week period, reaching a minimal count of approximately 500 cells/microlitre or approximately 30 % of baseline. Eighteen percent of patients reached a minimal count below 200 cells/microlitre on at least one occasion. Low lymphocyte counts are maintained with chronic daily dosing. The majority of T and B lymphocytes regularly traffic through lymphoid organs and these are the cells mainly affected by fingolimod. Approximately 15-20 % of T lymphocytes have an effector memory phenotype, cells that are important for peripheral immune surveillance. Since this lymphocyte subset typically does not traffic to lymphoid organs, it is not affected by fingolimod. Peripheral lymphocyte count increases are evident within days of stopping fingolimod treatment and typically normal counts are reached within one to two months. Chronic fingolimod dosing leads to a mild decrease in the neutrophil count to approximately 80 % of baseline. Monocytes are unaffected by fingolimod.</p><p><u>&nbsp;</u></p><p>Fingolimod causes a transient reduction in heart rate and decrease in atrioventricular conduction at treatment initiation (see sections 4.4 and 4.8). The maximal decline in heart rate is seen within 6 hours post-dose, with 70 % of the negative chronotropic effect achieved on the first day. With continued administration heart rate returns to baseline within one month. The decrease in heart rate induced by fingolimod can be reversed by parenteral doses of atropine or isoprenaline. Inhaled salmeterol has also been shown to have a modest positive chronotropic effect. With initiation of fingolimod treatment there is an increase in atrial premature contractions, but there is no increased rate of atrial fibrillation/flutter or ventricular arrhythmias or ectopy. Fingolimod treatment is not associated with a decrease in cardiac output. Autonomic responses of the heart, including diurnal variation of heart rate and response to exercise, are not affected by fingolimod treatment.</p><p><u>&nbsp;</u></p><p>S1P4 could partially contribute to the effect but was not the main receptor responsible for the lymphoid depletion. The mechanism of action of bradycardia and vasoconstriction were also studied <em>in vitro</em> in guinea pigs and isolated rabbit aorta and coronary artery. It was concluded that bradycardia could be mediated primarily by activation of inward-rectifying potassium channel or G-protein activated inwardly rectifying K<sup>+</sup> channel (IKACh/GIRK) and that vasoconstriction seems to be mediated by a Rho kinase and calcium dependent mechanism.</p><p><u>&nbsp;</u></p><p>Fingolimod treatment with single or multiple doses of 0.5 and 1.25 mg for two weeks is not associated with a detectable increase in airway resistance as measured by FEV<sub>1</sub> and forced expiratory flow rate</p><p>(FEF) 25-75. However, single fingolimod doses &ge; 5 mg (10-fold the recommended dose) are associated with a dose-dependent increase in airway resistance. Fingolimod treatment with multiple doses of 0.5, 1.25, or 5 mg is not associated with impaired oxygenation or oxygen desaturation with exercise or an increase in airway responsiveness to methacholine. Subjects on fingolimod treatment have a normal bronchodilator response to inhaled beta-agonists.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p>The efficacy of fingolimod has been demonstrated in two studies which evaluated once-daily doses of fingolimod 0.5 mg and 1.25 mg in adult patients with relapsing-remitting multiple sclerosis (RRMS). Both studies included adult patients who had experienced &ge; 2 relapses in the prior 2 years or &ge; 1 relapse during the prior year. Expanded Disability Status Score (EDSS) was between 0 and 5.5. A third study targeting the same adult patient population was completed after registration of fingolimod.</p><p><u>&nbsp;</u></p><p>Study D2301 (FREEDOMS) was a 2-year randomised, double-blind, placebo-controlled Phase III study of 1,272 patients (n=425 on 0.5 mg, 429 on 1.25 mg, 418 on placebo). Median values for baseline characteristics were: age 37 years, disease duration 6.7 years and EDSS score 2.0. Outcome results are shown in Table 1. There were no significant differences between the 0.5 mg and the 1.25 mg doses as regards either endpoint.</p><p><u>&nbsp;</u></p><p><strong>Table 1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study D2301 (FREEDOMS): main results</strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Fingolimod</strong></p><p><strong>0.5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical endpoints</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Annualised relapse rate (primary endpoint)</p></td><td style="vertical-align:top"><p>0.18**</p></td><td style="vertical-align:top"><p>0.40</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of patients remaining relapse-free at 24 months</p></td><td style="vertical-align:top"><p>70 %**</p></td><td style="vertical-align:top"><p>46 %</p></td></tr><tr><td style="vertical-align:top"><p>Proportion with 3-month Confirmed Disability Progression<sup>&dagger;</sup></p><p>Hazard ratio (95 % CI)</p></td><td style="vertical-align:top"><p>17 %</p><p>&nbsp;</p><p>&nbsp;</p><p>0.70 (0.52, 0.96)*</p></td><td style="vertical-align:top"><p>24 %</p></td></tr><tr><td style="vertical-align:top"><p><strong>MRI endpoints</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of new or enlarging T2 lesions over 24 months</p></td><td style="vertical-align:top"><p>0.0 (2.5)**</p></td><td style="vertical-align:top"><p>5.0 (9.8)</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of Gd-enhancing lesions at month 24</p></td><td style="vertical-align:top"><p>0.0 (0.2)**</p></td><td style="vertical-align:top"><p>0.0 (1.1)</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) % change in brain volume over 24 months</p></td><td style="vertical-align:top"><p>-0.7 (-0.8)**</p></td><td style="vertical-align:top"><p>-1.0 (-1.3)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>&dagger;</sup> &nbsp;&nbsp;&nbsp;&nbsp; Disability progression defined as 1-point increase in EDSS confirmed 3 months later.</p><p>** &nbsp; p&lt;0.001,* p&lt;0.05, compared to placebo</p><p>All analyses of clinical endpoints were intent-to-treat. MRI analyses used evaluable dataset.</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p>Patients who completed the 24-month core FREEDOMS study could enter a dose-blinded extension study (D2301E1) and receive fingolimod. In total, 920 patients entered (n=331 continued on 0.5 mg,</p><p>289 continued on 1.25 mg, 155 switched from placebo to 0.5 mg and 145 switched from placebo to 1.25 mg). After 12 months (month 36), 856 patients (93 %) were still enrolled. Between months 24 and 36, the annualised relapse rate (ARR) for patients on fingolimod 0.5 mg in the core study who remained on 0.5 mg was 0.17 (0.21 in the core study). The ARR for patients who switched from placebo to fingolimod 0.5 mg was 0.22 (0.42 in the core study).</p><p>&nbsp;</p><p>Comparable results were shown in a replicate 2-year randomised, double-blind, placebo-controlled</p><p>Phase III study on fingolimod in 1,083 patients (n=358 on 0.5 mg, 370 on 1.25 mg, 355 on placebo) with RRMS (D2309; FREEDOMS 2). Median values for baseline characteristics were: age 41 years, disease duration 8.9 years, EDSS score 2.5.</p><p><u>&nbsp;</u></p><p><strong>Table 2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study D2309 (FREEDOMS 2): main results</strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Fingolimod</strong></p><p><strong>0.5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical endpoints</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Annualised relapse rate (primary endpoint)</p></td><td style="vertical-align:top"><p>0.21**</p></td><td style="vertical-align:top"><p>0.40</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of patients remaining relapse-free at 24 months</p></td><td style="vertical-align:top"><p>71.5 %**</p></td><td style="vertical-align:top"><p>52.7 %</p></td></tr><tr><td style="vertical-align:top"><p>Proportion with 3-month Confirmed Disability Progression<sup>&dagger;</sup></p><p>Hazard ratio (95 % CI)</p></td><td style="vertical-align:top"><p>25 %</p><p>&nbsp;</p><p>&nbsp;</p><p>0.83 (0.61, 1.12)</p></td><td style="vertical-align:top"><p>29 %</p></td></tr><tr><td style="vertical-align:top"><p><strong>MRI endpoints</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of new or enlarging T2 lesions over 24 months</p></td><td style="vertical-align:top"><p>0.0 (2.3)**</p></td><td style="vertical-align:top"><p>4.0 (8.9)</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of Gd-enhancing lesions at month 24</p></td><td style="vertical-align:top"><p>0.0 (0.4)**</p></td><td style="vertical-align:top"><p>0.0 (1.2)</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) % change in brain volume over 24 months</p></td><td style="vertical-align:top"><p>-0.71 (-0.86)**</p></td><td style="vertical-align:top"><p>-1.02 (-1.28)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>&dagger;</sup> &nbsp;&nbsp;&nbsp;&nbsp; Disability progression defined as 1-point increase in EDSS confirmed 3 months later.</p><p>** &nbsp; p&lt;0.001, compared to placebo</p><p>All analyses of clinical endpoints were intent-to-treat. MRI analyses used evaluable dataset.</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p>Study D2302 (TRANSFORMS) was a 1-year randomised, double-blind, double-dummy, active (interferon beta-1a)-controlled Phase III study of 1,280 patients (n=429 on 0.5 mg, 420 on 1.25 mg, 431 on interferon beta-1a, 30 &mu;g by intramuscular injection once weekly). Median values for baseline characteristics were: age 36 years, disease duration 5.9 years and EDSS score 2.0. Outcome results are shown in Table 3. There were no significant differences between the 0.5 mg and the 1.25 mg doses as regards study endpoints.</p><p><u>&nbsp;</u></p><p><strong>Table 3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study D2302 (TRANSFORMS): main results</strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Fingolimod</strong></p><p><strong>0.5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Interferon beta-1a</strong></p><p><strong>30 &mu;g</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical endpoints</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Annualised relapse rate (primary endpoint)</p></td><td style="vertical-align:top"><p>0.16**</p></td><td style="vertical-align:top"><p>0.33</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of patients remaining relapse-free at 12 months</p></td><td style="vertical-align:top"><p>83 %**</p></td><td style="vertical-align:top"><p>71 %</p></td></tr><tr><td style="vertical-align:top"><p>Proportion with 3-month Confirmed Disability Progression<sup>&dagger;</sup></p><p>Hazard ratio (95 % CI)</p></td><td style="vertical-align:top"><p>6 %</p><p>&nbsp;</p><p>&nbsp;</p><p>0.71 (0.42, 1.21)</p></td><td style="vertical-align:top"><p>8 %</p></td></tr><tr><td style="vertical-align:top"><p><strong>MRI endpoints</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of new or enlarging T2 lesions over 12 months</p></td><td style="vertical-align:top"><p>0.0 (1.7)*</p></td><td style="vertical-align:top"><p>1.0 (2.6)</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of Gd-enhancing lesions at 12 months</p></td><td style="vertical-align:top"><p>0.0 (0.2)**</p></td><td style="vertical-align:top"><p>0.0 (0.5)</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) % change in brain volume over 12 months</p></td><td style="vertical-align:top"><p>-0.2 (-0.3)**</p></td><td style="vertical-align:top"><p>-0.4 (-0.5)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>&dagger;</sup> &nbsp;&nbsp;&nbsp;&nbsp; Disability progression defined as 1-point increase in EDSS confirmed 3 months later.</p><p>* &nbsp;&nbsp;&nbsp; p&lt;0.01,** p&lt;0.001, compared to interferon beta-1a</p><p>All analyses of clinical endpoints were intent-to-treat. MRI analyses used evaluable dataset.</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p>Patients who completed the 12-month core TRANSFORMS study could enter a dose-blinded extension (D2302E1) and receive fingolimod. In total, 1,030 patients entered, however, 3 of these patients did not receive treatment (n=356 continued on 0.5 mg, 330 continued on 1.25 mg, 167 switched from interferon beta-1a to 0.5 mg and 174 from interferon beta-1a to 1.25 mg). After</p><p>12 months (month 24), 882 patients (86 %) were still enrolled. Between months 12 and 24, the ARR for patients on fingolimod 0.5 mg in the core study who remained on 0.5 mg was 0.20 (0.19 in the core study). The ARR for patients who switched from interferon beta-1a to fingolimod 0.5 mg was 0.33 (0.48 in the core study).</p><p>&nbsp;</p><p>Pooled results of Studies D2301 and D2302 showed a consistent and statistically significant reduction in annualised relapse rate compared to comparator in subgroups defined by gender, age, prior multiple sclerosis therapy, disease activity or disability levels at baseline.</p><p>&nbsp;</p><p>Further analyses of clinical trial data demonstrate consistent treatment effects in highly active subgroups of relapsing-remitting multiple sclerosis patients.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The efficacy and safety of once-daily doses of fingolimod 0.25 mg or 0.5 mg (dose selected based on body weight and exposure measurements) have been established in paediatric patients aged 10 to &lt;18 years with relapsing-remitting multiple sclerosis.</p><p>&nbsp;</p><p>Study D2311 (PARADIGMS) was a double-blind, double-dummy, active-controlled study with flexible duration up to 24 months, with 215 patients 10 to &lt;18 years old (n=107 on fingolimod, 108 on interferon beta-1a 30 &mu;g by intramuscular injection once weekly).</p><p>&nbsp;</p><p>Median values for baseline characteristics were: age 16 years, median disease duration 1.5 years and EDSS score 1.5. The majority of patients were Tanner stage 2 or higher (94.4 %) and were &gt; 40 kg (95.3 %). Overall, 180 (84 %) of patients completed the core phase on study medicinal product (n=99 [92.5 %] on fingolimod, 81 [75 %] on interferon beta-1a). Outcome results are shown in Table 4.</p><p>&nbsp;</p><p><strong>Table 4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study D2311 (PARADIGMS): main results</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Fingolimod</strong></p><p><strong>0.25 mg or 0.5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Interferon beta-1a </strong></p><p><strong>30 &mu;g</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical endpoints</strong></p></td><td style="vertical-align:top"><p>n=107</p></td><td style="vertical-align:top"><p>n=107<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Annualised relapse rate (primary endpoint)</p></td><td style="vertical-align:top"><p>0.122**</p></td><td style="vertical-align:top"><p>0.675</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of patients remaining relapse-free at 24 months</p></td><td style="vertical-align:top"><p>85.7**</p></td><td style="vertical-align:top"><p>38.8</p></td></tr><tr><td style="vertical-align:top"><p><strong>MRI endpoints</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Annualised rate of the number of new or newly enlarging T2 lesions</p></td><td style="vertical-align:top"><p>n=106</p></td><td style="vertical-align:top"><p>n=102</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted mean</p></td><td style="vertical-align:top"><p>4.393**</p></td><td style="vertical-align:top"><p>9.269</p></td></tr><tr><td style="vertical-align:top"><p>Number of Gd-enhancing T1 lesions per scan up to month 24</p></td><td style="vertical-align:top"><p>n=105</p></td><td style="vertical-align:top"><p>n=95</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted mean</p></td><td style="vertical-align:top"><p>0.436**</p></td><td style="vertical-align:top"><p>1.282</p></td></tr><tr><td style="vertical-align:top"><p>Annualised rate of brain atrophy from baseline up to month 24</p></td><td style="vertical-align:top"><p>n=96</p></td><td style="vertical-align:top"><p>n=89</p></td></tr><tr><td style="vertical-align:top"><p>Least Square Mean</p></td><td style="vertical-align:top"><p>-0.48*</p></td><td style="vertical-align:top"><p>-0.80</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>#</sup> &nbsp;&nbsp;&nbsp;&nbsp; One patient randomised to receive interferon beta-1a by intramuscular injection was unable to swallow the double-dummy medicinal product and discontinued from study. The patient was excluded from the full analysis and safety set.</p><p>* &nbsp;&nbsp;&nbsp; p&lt;0.05,** p&lt;0.001, compared to interferon beta-1a</p><p>All analyses of clinical endpoints were on the full analysis set.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic data were obtained in healthy adult volunteers, in renal transplant adult patients and in multiple sclerosis adult patients.</p><p>&nbsp;</p><p>The pharmacologically active metabolite responsible for efficacy is fingolimod phosphate.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Fingolimod absorption is slow (t<sub>max</sub> of 12-16 hours) and extensive (&ge; 85 %). The apparent absolute oral bioavailability is 93 % (95 % confidence interval: 79-111 %). Steady-state-blood concentrations are reached within 1 to 2 months following once-daily administration and steady-state levels are approximately 10-fold greater than with the initial dose.</p><p>&nbsp;</p><p>Food intake does not alter C<sub>max</sub> or exposure (AUC) of fingolimod. Fingolimod phosphate C<sub>max</sub> was slightly decreased by 34 % but AUC was unchanged. Therefore, fingolimod may be taken without regard to meals (see section 4.2).</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>Fingolimod highly distributes in red blood cells, with the fraction in blood cells of 86 %. Fingolimod</p><p>phosphate has a smaller uptake in blood cells of &lt; 17 %. Fingolimod and fingolimod phosphate are</p><p>highly protein bound (&gt; 99 %).</p><p>&nbsp;</p><p>Fingolimod is extensively distributed to body tissues with a volume of distribution of about 1,200 &plusmn; 260 litres. A study in four healthy subjects who received a single intravenous dose of a radioiodolabelled analogue of fingolimod demonstrated that fingolimod penetrates into the brain. In a</p><p>study in 13 male multiple sclerosis patients who received fingolimod 0.5 mg/day, the mean amount of</p><p>fingolimod (and fingolimod phosphate) in seminal ejaculate, at steady-state, was approximately 10,000 times lower than the oral dose administered (0.5 mg).</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p>Fingolimod is transformed in humans by reversible stereoselective phosphorylation to the</p><p>pharmacologically active (S)-enantiomer of fingolimod phosphate. Fingolimod is eliminated by</p><p>oxidative biotransformation catalysed mainly via CYP4F2 and possibly other isoenzymes and</p><p>subsequent fatty acid-like degradation to inactive metabolites. Formation of pharmacologically</p><p>inactive non-polar ceramide analogues of fingolimod was also observed. The main enzyme involved</p><p>in the metabolism of fingolimod is partially identified and may be either CYP4F2 or CYP3A4.</p><p>&nbsp;</p><p>Following single oral administration of [<sup>14</sup>C] fingolimod, the major fingolimod-related components in</p><p>blood, as judged from their contribution to the AUC up to 34 days post-dose of total radiolabelled</p><p>components, are fingolimod itself (23 %), fingolimod phosphate (10 %) and inactive metabolites (M3</p><p>carboxylic acid metabolite (8 %), M29 ceramide metabolite (9 %) and M30 ceramide metabolite (7 %)).</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>Fingolimod blood clearance is 6.3 &plusmn; 2.3 L/h and the average apparent terminal half-life (t<sub>1/2</sub>) is</p><p>6-9 days. Blood levels of fingolimod and fingolimod phosphate decline in parallel in the terminal</p><p>phase, leading to similar half-lives for both.</p><p>&nbsp;</p><p>After oral administration, about 81 % of the dose is slowly excreted in the urine as inactive</p><p>metabolites. Fingolimod and fingolimod phosphate are not excreted intact in urine but are the major</p><p>components in the faeces, with amounts representing less than 2.5 % of the dose each. After 34 days,</p><p>the recovery of the administered dose is 89 %.</p><p><u>&nbsp;</u></p><p><u>Linearity</u></p><p>Fingolimod and fingolimod phosphate concentrations increase in an apparently dose proportional</p><p>manner after multiple once-daily doses of 0.5 mg or 1.25 mg.</p><p><u>&nbsp;</u></p><p><u>Characteristics in specific groups of patients</u></p><p>The pharmacokinetics of fingolimod and fingolimod phosphate do not differ in males and females, in</p><p>patients of different ethnic origin or in patients with mild to severe renal impairment.</p><p>&nbsp;</p><p>In subjects with mild, moderate or severe hepatic impairment (Child-Pugh class A, B and C), no</p><p>change in fingolimod C<sub>max</sub> was observed, but fingolimod AUC was increased respectively by 12 %,</p><p>44 % and 103 %. In patients with severe hepatic impairment (Child-Pugh class C), fingolimod phosphate C<sub>max</sub> was decreased by 22 % and AUC was not substantially changed. The pharmacokinetics of fingolimod phosphate were not evaluated in patients with mild or moderate hepatic impairment. The apparent elimination half-life of fingolimod is unchanged in subjects with mild hepatic impairment, but is prolonged by about 50 % in patients with moderate or severe hepatic impairment.</p><p>&nbsp;</p><p>Fingolimod should not be used in patients with severe hepatic impairment (Child-Pugh class C) (see</p><p>section 4.3). Fingolimod should be introduced cautiously in mild and moderate hepatic impaired</p><p>patients (see section 4.2).</p><p>&nbsp;</p><p>Clinical experience and pharmacokinetic information in patients aged above 65 years are limited.</p><p>Fingolimod should be used with caution in patients aged 65 years and over (see section 4.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>In paediatric patients (10 years of age and above) fingolimod-phosphate concentrations increase in an apparent dose proportional manner between 0.25 mg and 0.5 mg.</p><p>&nbsp;</p><p>Fingolimod-phosphate concentration at steady state is approximately 25 % lower in paediatric patients (10 years of age and above) following daily administration of 0.25 mg or 0.5 mg fingolimod compared to the concentration in adult patients treated with fingolimod 0.5 mg once daily.</p><p>&nbsp;</p><p>There are no data available for paediatric patients below 10 years old.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The preclinical safety profile of fingolimod was assessed in mice, rats, dogs and monkeys. The major target organs were the lymphoid system (lymphopenia and lymphoid atrophy), lungs (increased weight, smooth muscle hypertrophy at the bronchio-alveolar junction) and heart (negative chronotropic effect, increase in blood pressure, perivascular changes and myocardial degeneration) in several species; blood vessels (vasculopathy) in rats only at doses of 0.15 mg/kg and higher in a 2-year study, representing an approximate 4-fold margin based on the human systemic exposure (AUC) at a daily dose of 0.5 mg.</p><p>&nbsp;</p><p>No evidence of carcinogenicity was observed in a 2-year bioassay in rats at oral doses of fingolimod up to the maximally tolerated dose of 2.5 mg/kg, representing an approximate 50-fold margin based on human systemic exposure (AUC) at the 0.5 mg dose. However, in a 2-year mouse study, an increased incidence of malignant lymphoma was seen at doses of 0.25 mg/kg and higher, representing an approximate 6-fold margin based on the human systemic exposure (AUC) at a daily dose of 0.5 mg.</p><p>&nbsp;</p><p>Fingolimod was neither mutagenic nor clastogenic in animal studies.</p><p>&nbsp;</p><p>Fingolimod had no effect on sperm count/motility or on fertility in male and female rats up to the highest dose tested (10 mg/kg), representing an approximate 150-fold margin based on human systemic exposure (AUC) at a daily dose of 0.5 mg.</p><p>&nbsp;</p><p>Fingolimod was teratogenic in the rat when given at doses of 0.1 mg/kg or higher. Active substance exposure in rats at this dose was similar to that in patients at the therapeutic dose (0.5 mg). The most common foetal visceral malformations included persistent truncus arteriosus and ventricular septum defect. The teratogenic potential in rabbits could not be fully assessed, however, an increased embryo-foetal mortality was seen at doses of 1.5 mg/kg and higher and a decrease in viable foetuses as well as foetal growth retardation was seen at 5 mg/kg. Active substance exposure in rabbits at these doses was similar to that in patients.</p><p>&nbsp;</p><p>In rats, F1 generation pup survival was decreased in the early postpartum period at doses that did not cause maternal toxicity. However, F1 body weights, development, behaviour and fertility were not affected by treatment with fingolimod.</p><p>&nbsp;</p><p>Fingolimod was excreted in milk of treated animals during lactation at concentrations 2-fold to 3-fold higher than that found in maternal plasma. Fingolimod and its metabolites crossed the placental barrier in pregnant rabbits.</p><p><u>&nbsp;</u></p><p><u>Juvenile animal studies</u></p><p>Results from two toxicity studies in juvenile rats showed slight effects on neurobehavioural response, delayed sexual maturation and a decreased immune response to repeated stimulations with keyhole limpet haemocyanin (KLH), which were not considered adverse. Overall, the treatment-related effects of fingolimod in juvenile animals were comparable to those seen in adult rats at similar dose levels with the exception of changes in bone mineral density and neurobehavioural impairment (reduced auditory startle response) observed at doses of 1.5 mg/kg and higher in juvenile animals and the absence of smooth muscle hypertrophy in the lungs of the juvenile rats.</p><p><u>&nbsp;</u></p><p><u>Environmental Risk Assessment (ERA)</u></p><p>A risk for the environment due to use of fingolimod by patients with relapsing multiple sclerosis is not expected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule fill</u></p><p>Tricalcium phosphate</p><p>Stearic acid 50</p><p>&nbsp;</p><p><u>Capsule shell</u></p><p>Gelatin</p><p>Titanium dioxide (E171), and iron oxide yellow (E172).</p><p>&nbsp;</p><p><u>Printing ink</u></p><p>Shellac</p><p>Iron oxide black (E172)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg; C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A cardboard box containing the appropriate number of PVC/PE/PVDC aluminium foil blisters with an appropriate number of capsules and an instruction leaflet.</p><p>&nbsp;</p><p><u>DK/H/3082/001/DC</u></p><p><u>Pack sizes:</u></p><p>Cartons containing 28 or 98 hard capsules.</p><p>&nbsp;</p><p><u>DK/H/3083/001/DC</u></p><p><u>Pack sizes:</u></p><p>Cartons containing 28 hard capsules</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturer:
PHARMATHEN INTERNATIONAL S.A.
Industrial Park Sapes,
Ropodi Prefecture,
Block No 5, Rodopi 69300
Greece

Marketing Authorization Holder & Secondary Packaging:
SPIMACO
Al-Qassim Pharmaceutical Plant
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	April 2022.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>